

# Glaucoma Surgical Treatments (for New Jersey Only)

**Policy Number:** CS050NJ.R  
**Effective Date:** October 1, 2023

[Instructions for Use](#)

Table of Contents	Page
<a href="#">Application</a> .....	1
<a href="#">Coverage Rationale</a> .....	1
<a href="#">Applicable Codes</a> .....	1
<a href="#">Description of Services</a> .....	2
<a href="#">Clinical Evidence</a> .....	3
<a href="#">U.S. Food and Drug Administration</a> .....	21
<a href="#">References</a> .....	22
<a href="#">Policy History/Revision Information</a> .....	27
<a href="#">Instructions for Use</a> .....	27

Related Policies
None

## Application

This Medical Policy only applies to the state of New Jersey.

## Coverage Rationale

**The following are proven and medically necessary:**

- Goniotomy or gonioscopy-assisted transluminal trabeculotomy for pediatric glaucoma (age 18 years or less)
- [iStent®](#), [iStent inject®](#), or [Hydrus® Microstent](#) when used in combination with cataract surgery for treating mild to moderate open-angle glaucoma (OAG) and a cataract in adults currently being treated with ocular hypotensive medication
- Some glaucoma drainage devices (specifically XEN System, EX-PRESS, Molteno implant, Baerveldt tube shunt, Ahmed glaucoma valve implant, and Krupin-Denver valve implant) for treating refractory glaucoma when medical or surgical treatments have failed or are inappropriate

**The following are unproven and not medically necessary for treating any type of glaucoma due to insufficient evidence of efficacy and/or safety:**

- [Canaloplasty \(ab interno\)](#)
- [Combined canaloplasty \(ab interno\) and gonioscopy-assisted transluminal trabeculotomy](#) (e.g., OMNI® Surgical System)
- [Glaucoma drainage devices that are not FDA approved](#)
- [Goniotomy or gonioscopy-assisted transluminal trabeculotomy](#) (for all other indications)

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
*0253T	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space

CPT Code	Description
*0449T	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device
*0450T	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; each additional device (List separately in addition to code for primary procedure)
*0474T	Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space
*0671T	Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external reservoir, and without concomitant cataract removal, one or more
65820	Goniotomy
66174	Transluminal dilation of aqueous outflow canal (e.g., canaloplasty); without retention of device or stent
66175	Transluminal dilation of aqueous outflow canal (e.g., canaloplasty); with retention of device or stent
66179	Aqueous shunt to extraocular equatorial plate reservoir, external approach; without graft
66180	Aqueous shunt to extraocular equatorial plate reservoir, external approach; with graft
66183	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach
66989	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (e.g., irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (e.g., iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with insertion of intraocular (e.g., trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more
66991	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (e.g., irrigation and aspiration or phacoemulsification); with insertion of intraocular (e.g., trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more

*CPT® is a registered trademark of the American Medical Association*

Codes labeled with an asterisk (\*) are not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the State of New Jersey Medicaid Program.

HCPCS Code	Description
*C1889	Implantable/insertable device, not otherwise classified
*L8612	Aqueous shunt

## Description of Services

Glaucoma refers to a group of eye diseases in which vision is lost due to damage of the optic nerve. The 2016 American Academy of Ophthalmology (AAO) Preferred Practice Patterns Guidelines on primary open-angle glaucoma (POAG) states that the severity of glaucoma damage can be estimated using the following:

- Mild: Optic nerve abnormalities consistent with glaucoma and a normal visual field as tested with standard automated perimetry (SAP)
- Moderate: Optic nerve abnormalities consistent with glaucoma and visual field abnormalities in one hemifield that are not within 5 degrees of fixation as tested with SAP
- Severe: Optic nerve abnormalities consistent with glaucoma and visual field abnormalities in both hemifields and/or loss within 5 degrees of fixation in at least one hemifield as tested with SAP
- Indeterminate: Optic nerve abnormalities consistent with glaucoma, inability to perform visual field testing, unreliable/uninterpretable visual field test results, or visual fields not yet performed

Canaloplasty is a surgical technique for glaucoma which aims to restore the natural drainage of fluid from the eye [National Institute for Health and Care Excellence (NICE), 2008; updated 2017]. It was historically performed using an ab externo (from the outside) approach or more recently, an ab interno (from the inside) approach. Both approaches involve

viscodilation of Schlemm's canal (SC) to restore normal aqueous outflow. With an ab externo approach, the microcatheter is inserted through cuts in the conjunctiva and sclera and then, uses an intracanalicular suture that cinches and stretches the trabecular meshwork inwards while permanently opening the SC. With an ab interno approach, the microcatheter is inserted through either a clear corneal or limbal micro-incision, through the trabecular meshwork and then, into SC. Once in the canal, a viscoelastic gel is used to dilate it.

Trabeculectomy is described as a surgical procedure that removes part of the eye's trabecular meshwork and adjacent structures to reduce intraocular pressure (IOP) in individuals with glaucoma. For the majority of individuals, it is the most common surgery that allows drainage of aqueous humor from within the eye to underneath the conjunctiva where it is absorbed. Goniotomy is described as a surgical procedure where the trabecular meshwork is incised and/or excised with a blade or other surgical instrument for a least several clock hours to create an opening into the SC from the anterior chamber (AC), via an internal approach through the AC (AAO, 2023). Examples of devices which may be used during the goniotomy (also known as ab interno trabeculectomy) may include the Kahook Dual Blade (KDB) or Trabectome.

Gonioscopy-assisted transluminal trabeculectomy (GATT) is a refinement of circumferential ab interno trabeculectomy. With GATT, a temporal corneal wound is made and direct gonioscopy is used to visualize the nasal angle structures. A goniotomy is created and microsurgical forceps are used to guide an illuminated microcatheter or suture into SC. The forceps are used to progress the microcatheter or suture circumferentially until the tip is identified at the original goniotomy site and retrieved. Then, traction on the suture or catheter used to create a 360-degree trabeculectomy (Baykara, 2019, SooHoo, 2015).

Canalostomy (ab interno) and GATT involves the use of two different mechanistic modalities successively to address multiple points of outflow resistance in the conventional outflow pathway, both proximal and distal. First, canaloplasty is performed to open a distal outflow pathway including a collector channel ostium then, trabeculectomy removes the resistance residing in the trabecular meshwork (Vold, 2021).

Glaucoma drainage devices (also known as aqueous shunts) include the EX-PRESS™ Mini Glaucoma Shunt, the Molteno implant, the Baerveldt tube shunt, Ahmed glaucoma valve implant and the Krupin-Denver valve implant. The EX-PRESS™ Mini Glaucoma Shunt is a small stainless-steel device that is placed beneath the scleral flap into the AC instead of creating a punch or excisional sclerostomy, thereby bypassing the trabecular meshwork and directing aqueous fluid to form a perilimbal conjunctiva-covered bleb. The Molteno, Baerveldt and Ahmed glaucoma implants consist of a length of flexible plastic tubing that is inserted into anterior or posterior chamber and connect to a plastic or silicone plate with a large surface area that is secured to the posterior sclera between 2 of the extraocular muscles and covered by conjunctiva. The plate acts as a physical barrier to scarring of the conjunctiva to the sclera providing a large surface area bleb posterior to the limbus. The Krupin-Denver valve implant has a pressure sensitive unidirectional valve to provide filtration restriction and the implant is designed to open when IOP is > 11 mmHg (Krupin, 1988).

Glaucoma drainage devices such as iStent® and iStent *inject*® Trabecular Micro-Bypass systems, Eyepass, or DeepLight SOLX® Gold Shunt (suprachoroidal shunt) divert aqueous fluid from the AC directly into SC (Samuelson, 2008). The XEN® Gel Stent is for use in individuals with refractory glaucoma. A gelatin tube is implanted into the subconjunctival space and is proposed as a less traumatic alternative to ab externo procedures such as trabeculectomy and shunt implantation (AqueSys, Inc., 2017). These stenting/shunting procedures are similar to viscocanalostomy in that they lower IOP without the formation of a filtering bleb.

Micro-invasive or minimally invasive glaucoma surgery (MIGS) refers to a group of newer surgical procedures that are performed via an ab interno approach and involve minimal trauma to ocular tissues. Although less effective in lowering IOP than trabeculectomy and aqueous shunt surgery, MIGS may have a more favorable safety profile in the short term and is commonly combined with phacoemulsification. Examples of MIGS are the iStent *inject*® and the Hydrus® Microstent (AAO, 2016).

## Clinical Evidence

### Goniotomy or Gonioscopy-Assisted Transluminal Trabeculectomy for Pediatric Glaucoma (Age 18 Years or Less)

In 2021, Qiao et al. compared the efficacy and safety of GATT and Kahook Dual Blade (KDB) excisional goniotomy in patients with uncontrolled juvenile open-angle glaucoma (JOAG). Thirty-three patients (ages 4-40) were included in this single-center, retrospective, comparative study and treated with GATT (36 eyes) or KDB goniotomy (13 eyes). During pre- and postoperative visits, IOP, glaucoma medication usage, adverse events (AEs) and additional anti-glaucoma procedures were collected. Cumulative proportion of partial and complete success were 65.6 and 44.7% in the GATT

group, 30.8 and 15.4% in the KDB group at 6 months. Additional procedures were required in 13.9% of cases after GATT and in 61.5% after KDB ( $p = 0.001$ ). Participants in the GATT group with prior anti-glaucoma procedures and postoperative IOP spike were more likely to fail, while those with complete trabeculotomy had a better prognosis. The authors concluded reduction of IOP, and medications were greater after GATT in uncontrolled JOAG eyes. Whereas more additional IOP-lowering procedures were required after KDB goniotomy. The authors recommended future studies are needed to confirm the discrepancy in efficacy and safety between the two surgical approaches with larger sample sizes and prospective randomized designs. Limitations of this study include small sample size, limited follow-up evaluation, and retrospective nature of the study.

Gagrani et al. (2020) updated a previously conducted systematic review (Ghate, 2015) that aimed to compare the effectiveness and safety of various surgical techniques for primary congenital glaucoma (PCG). A search was conducted using Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase, PubMed, *metaRegister* of Controlled Trials (*mRCT*), ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (ICTRP). A total of 16 trials [13 randomized controlled trials (RCTs) and 3 quasi-RCTs] with 587 eyes in 446 children were included in the review. Three trials (on 68 children) compared combined trabeculotomy and trabeculectomy (CTT) with trabeculotomy, 2 trials (on 39 children) compared viscotrabeculotomy to conventional trabeculotomy, 2 trials (on 95 children) compared microcatheter-assisted 360-degree circumferential trabeculotomy to conventional trabeculotomy, 1 trial compared CTT versus CTT with sclerectomy; 3 trials compared various suturing techniques and adjuvant use including mitomycin C, collagen implant in CTT; 1 trial compared CTT versus Ahmed valve implant in previously failed surgeries; 1 trial compared CTT with trabeculectomy; 1 trial compared trabeculotomy to goniotomy, and 2 trials compared different types of goniotomy. The authors concluded that evidence on the comparative benefits and risks of different surgical procedures for PCG is limited however, microcatheter-assisted 360-degree trabeculotomy is probably more beneficial than standard trabeculotomy, but probably causes more unwanted effects. The authors also stated that considering the rarity of the disease, future research would benefit from a multicenter, possibly international trial, involving parents of children with PCG and with a follow-up of at least one year.

Huang et al. (2018) conducted a single-center cohort study to investigate the long-term postoperative outcome of three surgical procedures for childhood glaucoma. The investigators retrospectively reviewed the medical records of patients with several types of childhood glaucoma and based on the initial surgery, categorized patients into goniotomy, trabeculotomy, or filtering surgery groups. The main outcome measure was the probability of success of surgery based on a Kaplan–Meier analysis. Surgical failure was defined as one of the following: 1) when additional glaucoma filtering surgery was performed; 2) visual acuity deteriorated to an absence of light perception; and 3) an IOP greater than or equal to 21 mmHg with ocular hypotensive medications, verified during two consecutive visits. A total of 73 eyes of 43 patients were analyzed. The age at the initial surgery was  $4.1 \pm 6.4$  years (mean  $\pm$ SD; range: 1 month to 17.7 years). The follow-up period was  $9.6 \pm 6.7$  years (range: 2–20 years). Forty eyes of 25 patients, 21 eyes of 15 patients, and 12 eyes of 7 patients underwent initial surgery with goniotomy, trabeculotomy, and filtering surgery, respectively. The probability of success was  $65.2\% \pm 7.8\%$  and  $65.2\% \pm 7.8\%$  (estimated probability  $\pm$ standard error) at 10 and 20 years after the initial surgery, respectively, in the goniotomy group. It was  $42.2\% \pm 13.6\%$  at 10 years in the trabeculotomy group (no data for 20 years), and  $91.7\% \pm 8.0\%$  and  $80.2\% \pm 12.8\%$  at 10 and 20 years after the initial surgery in the filtering surgery group. The authors concluded that all three procedures maintained an IOP of less than 21 mmHg for up to 10 years and therefore, provide valuable options for the treatment of childhood glaucoma.

Yeung and Walton (2010) conducted a retrospective case series study to report outcomes of patients with acquired JOAG who underwent goniotomy surgery. Medical records from 10 patients were reviewed (20 goniotomy procedures, 17 eyes). The investigators reviewed sex, ethnicity, family history, refraction, preoperative gonioscopic findings, surgical outcome, age at initial goniotomy, duration of postoperative observation, preoperative and postoperative IOP, and glaucoma medication used. Complete success was defined as an IOP  $\leq$  21 mmHg, qualified success as IOP  $\leq$  21 mmHg with use of glaucoma medications, and failure as IOP  $>$  21 mmHg despite medical therapy. The surgical technique used to perform the goniotomy procedures was reviewed and the absence of significant complications noted. Overall surgical success was achieved in 77% (13/17) of the eyes. Average IOP for complete success (9 eyes) was  $14.7 \pm 2.1$  mmHg (range: 12 to 18 mmHg), qualified success (4 eyes)  $16.5 \pm 2.4$  mmHg (range: 14 to 19 mmHg), and failure (4 eyes)  $33.5 \pm 5.7$  mmHg (range: 30 to 42 mmHg). The mean age at surgery was  $16.3 \pm 8.1$  years (range: 7.3 to 32 years). Mean follow-up interval was  $7.8 \pm 6.2$  years (range: 0.1 to 16.3 years). Gonioscopy demonstrated normal appearing filtration angles in all eyes. No significant surgical complications occurred. Mean refractive error was  $-3.3 \pm 2.8$  (range: 0.0 to -7.8). Sixty percent of patients possessed a family history of JOAG. The authors concluded that goniotomy is a potentially effective initial surgical treatment of JOAG and that it can be successfully performed using a standard goniotomy technique. This study is limited by the lack of a comparison group.

Ho et al. (2004) conducted a retrospective case series study to describe the safety and efficacy of goniotomy in medically uncontrolled glaucoma complicating chronic childhood uveitis and the factors affecting its outcome. The main outcome



measures were IOP at the last follow-up and time to surgical failure. Success was defined as final IOP of no greater than 21 mmHg without medications and qualified success as IOP of no greater than 21 mmHg with medications. The secondary outcome measure was the number of medications needed to achieve an IOP of no greater than 21 mmHg after surgery. All goniotomies were performed by a single surgeon. Fifty-four goniotomies were performed in 40 eyes of 31 patients. Juvenile rheumatoid arthritis–associated uveitis was the diagnosis in 30 eyes (75%). Eleven eyes (28%) were aphakic. Mean follow-up was 98.9 months (range, 2 to 324 months). Mean age at surgery was 10.3 ±4.7 years (range, 4 to 22 years). Mean preoperative IOP was 36.7 ±6.4 mmHg while receiving a mean of 2.9 ±1.1 medications. Overall surgical success was achieved in 29 eyes (72%), including success in 22 (55%) and qualified success in 7 (18%) while receiving a mean of 1.6 ±1.1 medications. Mean postoperative IOP in the success and qualified-success groups were 14.3 ±2.8 and 15.7 ±3.1 mmHg, respectively. Kaplan-Meier survival probabilities (95% confidence interval) at 1, 5, and 10 years were 0.92 (0.82 to 1.00), 0.81 (0.65 to 0.97), and 0.71 (0.49 to 0.92), respectively. Phakic eyes, eyes with fewer peripheral anterior synechiae, patients younger than 10 years, and eyes with no prior surgery had significantly better outcomes. Hyphema, typically mild and transient, occurred in 43 procedures (80%). The authors concluded that goniosurgery is low risk and effective for refractory glaucoma complicating chronic childhood uveitis and therefore, it should be considered the surgical procedure of choice for this condition. They also stated that surgical outcome is adversely affected by increased age, peripheral anterior synechiae, prior surgeries, and aphakia. This study is limited by the lack of a comparison group.

Gramer et al. (1997) conducted a single-center, retrospective case series study to obtain information about the development of visual acuity, visual field and cup-disc ratio of patients with PCG who underwent IOP-regulating goniotomy. A total of 196 patients who underwent goniotomy were contacted. Of those, 92 returned replies and the contact information of the treating ophthalmologists could be ascertained from 77 patients. Sixty of the 77 patients fulfilled the inclusion criteria, which included PCG and IOP-regulating goniotomy as the last surgery. In 76% of 106 eyes childhood glaucoma was diagnosed during the first year of life. In 72% of 60 eyes/patients with PCG one goniotomy was sufficient to reach a normal IOP. In 18% a second and in 10% a third goniotomy was necessary, but without influence on the visual outcome. Even in the groups of eyes with a preoperative IOP of more than 40 mmHg, preoperative corneal diameter of more than 13 mm and preoperative severe corneal opacity more than 50% reached a visual acuity of 0.4-1.2 and more than 80% had a normal visual field. Only 9% of the eyes showed a cup-disc ratio of 0.6 or more. The authors concluded that in patients with PCG, even with high preoperative IOP, large corneal diameters and severe corneal edemas, there was a good prognosis of visual outcome after goniotomy. This study is limited by the lack of a comparison group.

## ***Clinical Practice Guidelines***

### **American Academy of Ophthalmology (AAO)**

The AAO's report, Pediatric Glaucoma Surgery, states that there are many surgical options for the treatment of the pediatric glaucoma (e.g., PCG, aphakic glaucoma, and glaucoma associated with other ocular or systemic anomalies) including goniotomy, trabeculotomy, trabeculectomy, combined trabeculotomy and trabeculectomy, tube shunt surgery, cyclodestruction, and deep sclerectomy. The relative efficacy of these various procedures for specific diagnoses and clinical situations should be weighed against the specific risks associated with the procedures for individual patients (Chen, 2014).

### **iStent® and iStent Inject®**

Healey et al. (2021) conducted a systematic review and meta-analysis to evaluate the efficacy of iStent devices (iStent® and iStent inject®) when performed independently of cataract surgery in patients with OAG. A search was conducted using Embase.com (EMBASE and MEDLINE) as well as the Cochrane Library. All randomized trials were considered as well as non-randomized studies that included at least 6 months of follow-up or more than 10 eyes. Efficacy analyses included post-operative intraocular pressure and medication use, and the proportion of eyes free of ocular medication. Post-operative AEs were descriptively summarized. The literature search yielded a total of 760 citations and after further review, a total of 13 studies were included in the analysis. Those included 4 RCTs and 9 non-randomized or single-arm studies providing data for 778 eyes. In eyes implanted with iStent devices, a weighted mean intraocular pressure reduction of 31.1% was observed at 6–12 months. In studies reporting longer-term outcomes (36–48 months or 60 months), the weighted mean IOP reduction was 30.4% and 32.9%, respectively. The pooled weighted mean reduction in intraocular pressure from baseline across all studies at 6–12 months and 36–60 months post-stent implantation was 7.01 mmHg (95% CI: 5.91 to 8.11) and 6.59 mmHg (95% CI: 5.55 to 7.63), respectively. Medication burden was reduced by approximately 1.0 medication at 6–18 months and 1.2 medications at 36–60 months. AEs reported in more than 5% of participants included progression of pre-existing cataract/ cataract surgery and loss of BCVA but these rates were no different to those reported in comparator medical therapy study arms. The authors concluded that these results support the independent effect of the iStent trabecular bypass devices on intraocular pressure and medication burden for up to five years after treatment, and without the potential for confounding from cataract surgery.

Clement et al. (2019) conducted a retrospective multicenter case series of iStent *inject*<sup>®</sup> trabecular micro-bypass implantation with cataract. Eyes had mild to advanced glaucoma (predominantly primary open-angle, appositional angle-closure, or pseudoexfoliative glaucoma) or ocular hypertension (OHT) and cataract requiring surgery. Patients have been followed for 12 months, and follow-up is ongoing. Of the 290 total eyes that underwent surgery, 165 eyes had 12-month outcomes at the time of data collection and are included in this report. Mean IOP at one year reduced by 23.2%, with 95.8% of eyes achieving IOP of  $\leq 18$  mmHg vs. 60.6% preoperatively. Mean number of medications decreased by 71.5%, with 76.4% of eyes on zero medications at 12 months vs. 17.6% preoperatively. 98.2% of eyes maintained or reduced medications vs. their preoperative regimen. Safety profile was excellent, with only limited and transient postoperative AEs. The authors concluded that the iStent *inject*<sup>®</sup> combined with cataract surgery significantly and safely reduced medications and IOP in eyes with various types and severities of glaucoma. They also noted that future reports may assess longer-term outcomes and larger sample sizes, as well as include subgroup analyses of eyes with different glaucoma types or stratification by history of prior glaucoma surgery. This study is limited by the lack of a comparison group.

An ECRI review, iStent *inject* trabecular micro-bypass system for treating OAG during cataract surgery (2019), evaluated 7 studies (5 full text and 2 abstracts) with a total of 1,112 eyes. Those included 1 multicenter RCT, 1 single-center RCT, and 5 non-randomized comparison studies. Evidence from those studies showed that iStent *inject* implantation during cataract surgery reduced IOP ( $> 20\%$ ) and use of glaucoma medication for patients with mild-to-moderate primary OAG through two years of follow-up. Serious AEs did not differ statistically between iStent *inject* plus cataract surgery or cataract surgery alone. The authors concluded that the evidence is somewhat favorable.

Samuelson et al. (2019a) evaluated the safety and effectiveness of the iStent *inject*<sup>®</sup> trabecular micro-bypass system (Glaukos Corporation, San Clemente, CA, USA) in combination with cataract surgery in subjects with mild to moderate POAG through a prospective, single-masked, concurrently controlled, multicenter RCT (NCT00323284). After uncomplicated cataract surgery, eyes were randomized 3:1 intraoperatively to ab interno implantation (single or multiple) of iStent *inject*<sup>®</sup> (Model G2-M-IS; treatment group,  $n = 386$ ) or no stent implantation (control group,  $n = 118$ ). Subjects were followed for 2 years post-implant. At 24 months, 75.8% of treatment eyes versus 61.9% of control eyes experienced  $\geq 20\%$  reduction from baseline in unmedicated diurnal IOP (DIOP), and mean reduction in unmedicated DIOP from baseline was greater in treatment eyes ( $7.0 \pm 4.0$  mmHg) than in control eyes ( $5.4 \pm 3.7$  mmHg). Of the subjects who were responders (e.g., 24-month unmedicated mean DIOP reduced by  $\geq 20\%$  from baseline in the absence of IOP-affecting surgery during the study), 84% of treatment eyes and 67% of control group eyes were not receiving ocular hypotensive medication at 23 months. In addition, 63% of treatment eyes and 50% of control eyes had medication-free DIOP  $\leq 18$  mmHg at 2 years. The overall safety profiles were highly favorable and similar in both groups throughout the follow-up period. The researchers concluded that clinically and statistically greater reductions in IOP without medication were achieved after iStent *inject*<sup>®</sup> implantation with cataract surgery versus cataract surgery alone. Additionally, the pivotal study's findings support the consideration of this second-generation trabecular micro-bypass stent system as a safe, durable, and less compliance-dependent treatment modality for additional unmedicated IOP reduction in POAG eyes undergoing cataract surgery. This study was included in the ECRI review.

In a single-center, longitudinal, retrospective, comparative study, Guedes et al. (2019) performed a side-by-side comparison of the iStent<sup>®</sup> and iStent *inject*<sup>®</sup> trabecular micro-bypass stent systems. The study evaluated performance and safety in consecutive eyes following implantation of either device with concomitant cataract surgery. Performance outcomes included IOP reduction; glaucoma medication reduction; proportions of eyes achieving an IOP of  $< 18$ ,  $< 16$ ,  $< 14$ , or  $< 12$  mmHg; and proportions of eyes on 0, 1, 2, or  $\geq 3$  medications. Safety outcomes included AEs, secondary surgeries, and BCVA. The follow up period was 6 months. A total of 73 eyes with OAG and cataract were included in the study; of these, 38 eyes were implanted with the iStent<sup>®</sup> device and 35 were implanted with the iStent *inject*<sup>®</sup> device. At 6 months post-surgery, mean IOP had fallen in both groups; however, the reduction was significantly greater in the iStent *inject*<sup>®</sup> eyes versus the iStent<sup>®</sup> eyes (26.6 vs. 15.8%). All who received the iStent *inject*<sup>®</sup> device achieved an IOP of  $< 18$  mmHg at 6 months compared to 86.8% of the iStent<sup>®</sup> recipients, and  $> 70\%$  of eyes in both groups became medication-free by 6 months post implantation. AEs occurred in 2 iStent<sup>®</sup> eyes which resulted in no sequelae; and 2 iStent<sup>®</sup> eyes underwent non-penetrating deep sclerectomy during follow-up. No complications or secondary surgeries occurred in the iStent *inject*<sup>®</sup> group. All eyes in both groups maintained or showed improved BCVA versus baseline. The authors concluded that significant and safe IOP and medication reductions were observed after iStent<sup>®</sup> or iStent *inject*<sup>®</sup> implantation with concomitant cataract surgery. However, compared with the iStent<sup>®</sup>, trends toward greater effectiveness and fewer AEs were observed with the iStent *inject*<sup>®</sup>. This advantage may be attributed to device design: each individual iStent *inject*<sup>®</sup> stent has four lateral outflow lumens and uses two stents versus one in the trabecular meshwork which allows for greater IOP-reducing potential. Several limitations to the study include a modest number of eyes in each group, relatively short follow up period and lack of randomization. A prospective study with a larger population and longer follow-up is necessary to validate these findings. This study was included in the ECRI review.

The aim of a prospective, non-randomized, consecutive case series by Hengerer et al. (2018) was to assess 36-month outcomes after cataract surgery and implantation of two second-generation trabecular micro-bypass stents (iStent *inject*<sup>®</sup>). Participants (81 eyes of 55 consecutive patients) presented with cataract plus varying types of glaucoma (POAG/n = 60, pseudoexfoliative (PEX)/n = 5), appositional narrow angle/n = 4, pigmentary/n = 1) or neovascular (secondary)/n = 1). Following cataract surgery, all eyes underwent ab interno iStent *inject*<sup>®</sup> implantation. Effectiveness endpoints included IOP, number of medications, and proportion of eyes with  $\geq 20\%$  IOP reduction, IOP  $\leq 18$  mmHg, and IOP  $\leq 15$  mmHg. Safety measures included corrected distance visual acuity, AEs, and secondary surgeries. Outcomes were evaluated for the overall cohort, and for the POAG and PEX subgroups. In the overall cohort, substantial reductions in both IOP and medication use were observed for 36 months postoperatively. With regards to the POAG and PEX subgroups, the outcomes in PEX eyes were similarly favorable to those in POAG eyes, thereby corroborating prior studies showing iStent<sup>®</sup> technology to be a highly suitable and effective treatment option in patients with this condition. The authors concluded that the study demonstrated substantial reductions in both IOP and medication burden along with favorable safety through 36 months following the implantation of iStent *inject*<sup>®</sup>. While there were several limitations in this unmasked, single arm study, these outcomes were interpreted as significant and future studies are encouraged.

Popovic et al. (2018) conducted a systematic review and meta-analysis on the efficacy and adverse event (AE) profile of the iStent in the treatment of OAG. Using predetermined search terms, a systematic review was performed using Ovid MEDLINE and Ovid EMBASE. A total of 28 studies were included in the meta-analysis. The main analysis was performed based on whether patients had 1, 2 or 3 iStents implanted and whether they did or did not receive combined phacoemulsification and iStent. The mean age was  $71.4 \pm 5.4$  years, and 44.9% of patients were male. There was a significantly greater IOP reduction after the use of two first-generation stents compared to one, irrespective of phacoemulsification status ( $p < 0.001$ ). Additionally, there was a significantly greater IOP reduction following iStent alone relative to phaco-iStent for the first-generation iStent ( $p < 0.001$ ) and the iStent *inject* ( $p < 0.001$ ). For the first-generation stent, combined phaco-iStent provided a greater level of IOP reduction ( $p < 0.001$ ) and reduction in the number of medication classes relative to phacoemulsification alone ( $p < 0.001$ ). In total, 22.5% of eyes that received iStent implantation sustained some type of AE. The most common AEs were IOP elevation, stent blockage or obstruction, stent malposition and hyphema. The authors concluded that there may be differences in treatment response for the iStent due to varying parameters, including the number of iStents and phaco-iStent compared to either iStent alone or phacoemulsification alone. In their analysis, two stents delivered a greater response in terms of IOP reduction relative to one and iStent alone had a significantly greater IOP reduction compared to phaco-iStent. Combined phaco-iStent was statistically superior relative to phacoemulsification alone in the reduction of IOP and medication classes pre- to post-operatively. A retrospective, intraindividual eye study was conducted on 27 patients (54 eyes) with cataract and OAG to compare the safety and efficacy of combined micro-incision cataract surgery (MICS) in one eye with the ab interno trabeculectomy (AIT) with Trabectome<sup>®</sup> versus MIGS with two iStent *inject*<sup>®</sup> devices in the contralateral eye. Patients were followed for 6 weeks, 3-, 6-, and 12-months post-implantation. The authors concluded that the trabeculectomy and iStent *inject*<sup>®</sup> were both effective in lowering IOP with a favorable and comparable safety profile, citing no significant difference between the 2 approaches. Further research would be necessary to determine long-term outcomes and evaluate significant differences (Gonnermann et al., 2017). This study was included in the ECRI review.

In a prospective, interventional case series, Arriola-Villalobos and colleagues (2016) evaluated the long-term efficacy and safety of the iStent *inject*<sup>®</sup> device combined with phacoemulsification in 20 patients with coexistent cataract and OAG or OHT. Patients underwent cataract surgery along with the implant of two iStent *inject*<sup>®</sup> devices. Outcome measures were IOP, topical hypotensive medications required, and BCVA. Mean follow-up was  $47.4 \pm 18.46$  months. Mean end-follow-up IOP demonstrated a decrease of 36.92% from baseline washout IOP. Forty-five percent of patients were medication-free by the end of follow-up, and mean BCVA improved significantly. No complications of surgery were observed. The authors concluded that the iStent *inject*<sup>®</sup> device combined with cataract surgery significantly reduces both IOP and medication use in the long term in patients with coexistent OAG or OHT and cataract. Confirmation of these findings via RCTs with large patient cohorts is required. This study is limited by the lack of a comparison group.

Arriola-Villalobos et al. (2012) also evaluated the long-term efficacy and safety of combined cataract surgery and Glaukos iStent<sup>®</sup> implantation for coexistent OAG and cataract. This prospective case series included 19 patients. Mean follow-up was 53.68 months. Mean IOP was reduced from 19.42 mmHg at the end of follow up to 16.26 mm, representing a 16.33% decrease. The mean number of pressure-lowering medications used by the patients fell from 1.32 to 0.84. In 42% of patients, no antiglaucoma medications were used at the end of follow-up. Mean BCVA significantly improved from 0.29 to 0.62. The authors concluded that combined cataract surgery and iStent<sup>®</sup> implantation seems to be an effective and safe procedure to treat coexistent OAG and cataract. This study is limited by the lack of a comparison group.

In a prospective case series, Belovay et al. (2012) evaluated the efficacy and safety of multiple trabecular micro-bypass stents in forty-seven patients with cataract (53 eyes) to treat POAG. Either 2 ( $n = 26$ ) or 3 ( $n = 23$ ) stents were implanted along with concurrent cataract surgery. Efficacy measures were IOP and topical ocular hypotensive medication use.



Patients were followed for 1 year. The overall mean 1-year postoperative IOP was 14.3 mmHg, which was significantly lower than preoperative IOP overall and in each group. The target IOP was achieved in a significantly higher proportion of eyes at 1 year versus preoperatively (77% versus 43%). Overall, 83% of eyes had a decrease in topical ocular hypotensive medication at 1 year from preoperatively, with a 74% decrease in the mean number of medications (from 2.7 to 0.7) at 1 year. The 3-stent group was on significantly fewer medications than the 2-stent group at 1 year. The authors concluded that the use of multiple micro-bypass stents with concurrent cataract surgery led to a mean postoperative IOP of less than 15 mmHg and allowed patients to achieve target pressure control with significantly fewer medications through 1 year.

Samuelson et al. (2011) assessed the safety and efficacy of the iStent® trabecular micro-bypass stent in combination with cataract surgery in a prospective, open-label, multicenter randomized controlled trial (RCT). A total of 240 eyes with mild to moderate OAG with IOP ≤ 24 mmHg controlled on 1 to 3 medications were randomized to undergo cataract surgery with iStent® implantation (treatment group) or cataract surgery only (control). Fifty additional patients were enrolled to undergo cataract surgery with iStent® implantation under protocol expansion. The primary efficacy measure was unmedicated IOP ≤ 21 mmHg at 1 year. The study met the primary outcome, with 72% of treatment eyes versus 50% of control eyes achieving the criterion. At 1 year, IOP in both treatment groups was significantly lower from baseline values. Sixty-six percent of treatment eyes versus 48% of control eyes achieved 20% or more IOP reduction without medication. The overall incidence of AEs was similar between groups with no unanticipated adverse device effects. The investigators concluded that pressure reduction on fewer medications was clinically and statistically better 1 year after iStent® plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.

## **Hydrus® Microstent**

Ahmed et al. (2021) reported 3-year outcomes of the HORIZON study (Samuelson 2019b) which compared cataract surgery performed with Hydrus Microstent (HMS) implantation (n = 369) to that of cataract surgery (CS) alone (n = 187). The authors found the results suggested that combining the Hydrus Microstent implantation at the time of the cataract surgery improved the patient's chances of remaining medication free and reduced the risk of needing additional glaucoma surgery. No differences were found when it came to safety outcomes or long-term endothelial cell loss. Despite some limitations which included the exclusion of patients with secondary open angle glaucoma (SOAG) and limitation of only one comorbidity (POAG) for patients, the authors felt the study sufficiently demonstrated the difference in long-term IOP and medication reduction. In a 2022 update by Ahmed et al. after a five-year follow-up, outcomes measured IOP, glaucoma medication usage, repeat glaucoma surgery, visual acuity, visual field, AEs and corneal endothelial cell counts. The outcomes showed the HMS group included a higher proportion of eyes with IOP of 18 mmHg or less without medications than the CS group as well as greater likelihood of IOP reduction of 20% or more without medications than the CS group and 66% of eyes in the HMS group were medication free compared with 46% in the CS group. The authors concluded the microstent in conjunction with CS was safe, resulted in lowered IOP, medication use and reduced the need for postoperative incisional glaucoma filtration surgery compared with CS after 5 years. Study limitations included inability to mask the surgeon to treatment group during examinations, limited experience by the surgeons with the HMS implantation technique, exclusion of patients with SOAG, inclusion limitations to only POAG eyes with age-related cataract and possibly medication introduction bias.

Otarola et al. (2020) conducted a systematic review of RCTs to evaluate the efficacy and safety of ab interno trabecular bypass surgery with the Hydrus Microstent in treating patients with OAG. A search was conducted using the CENTRAL, Ovid MEDLINE, Ovid Embase, the International Standard Research Clinical Trial Number (ISRCTN) registry, the U.S. National Institutes of Health Ongoing Trials Register, and the World Health Organization (WHO) International Clinical Trials Registry Platform. A total of 209 publications were screened, and 3 studies (4 publications, Ahmed 2019, Jones 2018, Samuelson 2018, Pfeiffer 2015), with 808 randomized subjects were included in the review. Two studies compared the Hydrus Microstent combined with cataract surgery to cataract surgery alone, in participants with visually significant cataracts and OAG and the other study reported short-term data for the Hydrus Microstent compared with the iStent trabecular micro-bypass stent. The authors concluded that in patients with cataracts and mild to moderate OAG, there is moderate-certainty evidence that the Hydrus Microstent with cataract surgery compared to cataract surgery alone, likely increases the proportion of participants who do not require IOP lowering medication and may further reduce IOP at short- and medium-term follow-up. The authors also stated that there is moderate-certainty evidence that the Hydrus Microstent is probably more effective than the iStent in lowering IOP of patients with OAG in the short-term, complications may be rare using the Hydrus Microstent, as well as the iStent, and that because only a few Hydrus Microstent studies exist, additional larger studies are needed to fully investigate its safety.

An ECRI review, Hydrus Microstent for Treating OAG during Cataract Surgery (2019), evaluated 2 RCTs and 2 cohort studies. Evidence from those studies were considered to be somewhat favorable and showed that Hydrus implantation is safe and effective in normalizing IOP in patients with OAG; however, evidence gaps remain. The studies follow-up periods are limited to two years, which is insufficient to assess changes in visual acuity and vision-related quality of life in most



patients with early or mild-to-severe glaucoma. Randomized control trials with 5- to 10-years of follow-up are needed to assess the device's longevity and potential AEs are needed.

Al-Mugheiry and colleagues (2017) conducted a case series to evaluate learning effects with respect to outcomes when the Hydrus<sup>®</sup> Microstent is inserted during cataract surgery in glaucoma patients. Twenty-five patients were included with a minimum follow-up of 12 months. A learning curve analysis was performed by assessing hypotensive effect, AEs, and surgical procedure duration, with respect to consecutive case number. Success was defined with respect to various IOP targets (21, 18, 15 mmHg) and reduction in required antiglaucoma medications. Complete success was defined as achieving target IOP without antiglaucoma therapy. There were no significant AEs or learning effects identified, although surgical time reduced with consecutive case number. The researchers found no significant learning curve effects for a trained surgeon with respect to the MIGS microstent insertion performed at the time of cataract surgery. Adjunctive MIGS surgery using the Hydrus<sup>®</sup> Microstent was successful in lowering IOP and reducing/abolishing the requirement for antiglaucoma medication in eyes with OAG, but less successful at achieving low IOP levels. The findings are limited by the lack of a comparison group.

Fea et al. (2017a) conducted a prospective interventional cohort study comparing the reduction of IOP and glaucoma medications following selective laser trabeculoplasty (SLT) versus stand-alone placement of the Hydrus<sup>®</sup> Microstent. Participants with uncontrolled POAG (n = 56 eyes/56 patients) received either SLT (n = 25) or Hydrus<sup>®</sup> implantation (n = 31) at 2 centers. Patients were evaluated at baseline and 1 day, 7 days, 1-, 3-, 6- and 12-months post-surgery. Primary outcome measures were IOP and use of glaucoma medications. There were no significant differences at baseline between groups. After 12 months, the Hydrus<sup>®</sup> group had significant decreases in both IOP and medication use compared with baseline. In the SLT group, while there was a significant decrease in IOP, there was a 3-fold greater reduction in medication use in the Hydrus<sup>®</sup> group compared with SLT. At 12 months, 47% of patients versus 4% were medication-free in the Hydrus and SLT groups, respectively. In the SLT group, members were complication-free. Three patients in the Hydrus<sup>®</sup> group experienced a temporary reduction of visual acuity post-operatively, and 2 patients had post-operative IOP spikes that resolved within one week. The authors concluded that while both procedures are safe, the use of the Hydrus<sup>®</sup> implant led to a significant and further reduction in medication dependence at 12 months. The study is, however, limited by the lack of randomization.

Fea et al. (2017b) also conducted a multi-site retrospective case series, evaluating the safety and efficacy of the Hydrus<sup>®</sup> Microstent combined with cataract surgery in routine clinical practice. The study included 92 eyes and analyzed outcomes based on IOP, number of glaucoma medications, incidence of complications and baseline and at 2 years post procedure. The researchers concluded that combined phacoemulsification and implantation of the Hydrus<sup>®</sup> Microstent is an effective surgical treatment option in patients with OAG, including patients with previously failed incisional glaucoma surgeries. The combined surgery led to a significant reduction in IOP and a high medication-free rate 24 months postoperatively. The findings are however limited by the lack of a comparison group.

## **Glaucoma Drainage Devices Approved by the U.S. Food and Drug Administration (FDA)**

### ***EX-PRESS<sup>™</sup>***

Sun et al. (2019) conducted an updated meta-analysis of randomized controlled trials to compare the efficacy and safety of trabeculectomy and EX-PRESS implantation in OAG. The search was conducted using PubMed, Web of Science, Embase, and the Cochrane Library. Articles that met the predetermined search terms and published up to November 2018 were included. IOP reduction and antiglaucoma medication reduction were considered continuous variables with the mean difference (MD) measured. Complication, postoperative success, and intervention were considered dichotomous variables measured as the odds ratio (OR). Complete success was defined as target endpoint IOP without antiglaucoma medication, while qualified success was defined as target endpoint IOP with or without antiglaucoma medication. All outcomes were reported with a 95% confidence interval (CI). Data were pooled using a random effects model. A total of 8 RCTs were included in the final analysis (223 eyes in the EX-PRESS group and 217 eyes in the trabeculectomy group). EX-PRESS device implantation had a better IOPR% at 12 months postoperatively compared with trabeculectomy. There was no difference in the antiglaucoma medication reduction and qualified success between the groups. Complete success at 1 year postoperatively was higher in the EX-PRESS group (OR = 3.26, 95% CI = 1.24–8.55, p = 0.02). EX-PRESS was associated with a lower frequency of increased IOP (OR = 0.15, 95% CI = 0.03–0.93, p = 0.04) and hyphema (OR = 0.20, 95% CI = 0.05–0.74, p = 0.02). Less postoperative intervention was needed in the EX-PRESS group (OR = 0.43, 95% CI = 0.20–0.94, p = 0.04). The authors concluded that for OAG patients, EX-PRESS implantation provided better efficacy in IOP control and complete success at 1 year postoperatively, with fewer patients with increased IOP and hyphema as well as requiring postoperative interventions. The EX-PRESS device and trabeculectomy were similar in the qualified success and antiglaucoma medication reduction.

De Jong et al. (2011) published results from a 5-year extension of a prospective RCT conducted to establish the efficacy and safety of the EX-PRESS mini glaucoma shunt in OAG. In the original study (de Jong 2009), enrolled patients were randomly assigned to either EX-PRESS implantation under a scleral flap, or trabeculectomy. The main outcome measures included: mean IOP, postoperative medication use, visual acuity, and incidence of complications. Complete success was defined as an IOP of  $> 4$  mmHg and  $\leq 18$  mmHg without the use of antiglaucoma medications. A more stringent target of IOP  $> 4$  mmHg and  $\leq 15$  mmHg was also noted. A total of 78 patients (80 eyes) with primary open angle, pseudoexfoliative, or pigmentary glaucoma were enrolled. Of those, 84.6% of patients who were randomized to EX-PRESS and 60.0% of patients who were randomized to trabeculectomy achieved complete success ( $p = 0.0230$ ). Patients who achieved an IOP  $> 4$  mmHg and  $\leq 15$  mmHg were 76.9% and 50.0%, respectively ( $p = 0.0193$ ). At 1-year of follow-up, complete success rates were 81.8% for EX-PRESS and 47.5% for trabeculectomy ( $p = 0.0020$ ), and 71.7% and 37.5% ( $p = 0.0070$ ), respectively, for the more stringent target. There was a similar level of postoperative interventions and complications for each group. In the extension study, risk-benefit data for 78 patients who received either the EX-PRESS glaucoma filtration device or underwent a trabeculectomy were followed for up to an additional four years (five years total) beyond the original study (39 eyes per treatment group). Outcome variables were intraocular pressures and IOP medications. Complete success was denoted by IOP values  $\leq 18$  mmHg without medication. The EX-PRESS glaucoma filtration device controlled IOP more effectively without medication for more patients from year 1 (86.8% versus 61.5%,  $p = 0.01$ ) to year 3 (66.7% versus 41.0%,  $p = 0.02$ ) than trabeculectomy. At year 1, only 12.8% of patients required IOP medication after EX-PRESS implantation, compared with 35.9% after trabeculectomy. The proportions became closer at year 5 (41% versus 53.9%). The responder rate was higher with EX-PRESS and time to failure was longer. In addition, surgical interventions for complications were fewer after EX-PRESS implantation. The authors concluded that the five-year analysis confirmed and extended the results reported after one year, and that compared with trabeculectomy, EX-PRESS provided better IOP control in the first three years, and patients required fewer IOP medications and fewer surgical interventions during the five-year study period. They also concluded that for patients with POAG, the EX-PRESS glaucoma filtration device produced significantly higher success rates than trabeculectomy, and therefore the EX-PRESS is an effective device for long-term treatment of POAG. de Jong (2011) was included in the Sun 2019 systematic review described above.

### ***Molteno Implant, Baerveldt Tube Shunt, Ahmed Glaucoma Valve, and Krupin-Denver Value Implants***

Islamaj et al. (2020) conducted an RCT to compare Baerveldt glaucoma implant (BGI) surgery and trabeculectomy (TE) in patients without previous ocular surgery. Inclusion criteria were age 18–75 years, primary OAG, normal-tension glaucoma (NTG), pseudo exfoliative glaucoma or pigmentary glaucoma and the need for IOP lowering surgery. Patients with a history of any ocular surgery, such as TE, strabismus surgery or cataract extraction were excluded from the study. Other exclusion criteria were history of active uveitis or diabetic retinopathy, pregnancy or lactation, anticipated glaucoma surgery combined with other ocular procedures (i.e., cataract surgery), narrow AC angle interfering with tube implantation, BCVA  $< 0.1$  in the study eye or fellow eye and history of ocular motility disturbances. Primary outcomes were IOP and failure rate. Secondary outcomes were medication, AC laser flare value and complications. A total of 119 patients with glaucoma were included in the trial (60 patients received TE surgery and 59 received a BGI). After 5 years, an IOP of  $12.7 \pm 3.9$  mmHg (mean  $\pm$ SD) was achieved in the TE group and  $12.9 \pm 3.9$  mmHg in the BGI group. There was no difference in the failure rate between the groups ( $p = 0.72$ ). More BGI patients needed additional medication to control their IOP (85%;  $1.9 \pm 1.2$  types of glaucoma medication) compared to the TE patients (57%;  $0.5 \pm 0.9$  types of glaucoma medication). Diplopia was significantly more present in the BGI group than in the TE group (27% versus 4%;  $p < 0.001$ ). The self-limiting complication rate was similar in both groups. The authors concluded that, in the long term, the final IOP and failure rate are similar after TE and BGI surgery, and that the need for additional medication after BGI surgery is higher than after TE. They also stated that the increased risk of developing diplopia after BGI surgery must be taken into consideration.

In a Cochrane Review conducted by Tseng et al. (2017) the objective was to assess the effectiveness and safety of aqueous shunts for reducing IOP in glaucoma. A search was conducted in CENTRAL, MEDLINE Ovid, Embase.com, PubMed, LILACS (Latin American and Caribbean Health Sciences Literature Database), ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and included randomized controlled trials that compared various types of aqueous shunts with standard surgery or to each other in eyes with glaucoma. The search resulted in 27 relevant trials, which included a total of 2,099 participants. Four trials compared an aqueous shunt (Ahmed or Baerveldt) with trabeculectomy, 2 trials that compared the Ahmed implant with the Baerveldt implant, 1 trial compared the Ahmed implant with the Molteno implant, 2 trials compared the double-plate Molteno implant with the Schocket shunt, and the remaining 18 trials evaluated modifications to aqueous shunts. The authors concluded that information was insufficient to conclude whether there are differences between aqueous shunts and trabeculectomy for glaucoma treatment. While the Baerveldt implant may lower IOP more than the Ahmed implant, the evidence was of moderate-certainty, and it is unclear whether the difference in IOP reduction is clinically significant. Overall, methodology

and data quality among existing randomized controlled trials was heterogeneous across studies, and there are no well-justified or widely accepted generalizations about the superiority of one surgical procedure or device over another.

Budenz et al. (2011) evaluated the relative efficacy and complications of the Ahmed glaucoma valve (AGV) (New World Medical, Ranchos Cucamonga, CA) and the Baerveldt glaucoma implant (BGI) (Abbott Medical Optics, Abbott Park, IL) in refractory glaucoma in a multicenter, RCT. The study included 276 patients (143 = AGV group and 133 = BGI). Preoperative IOP was  $31.2 \pm 11.2$  mmHg in the AGV group and  $31.8 \pm 12.5$  mmHg in the BGI group. At 1 year, mean  $\pm$ SD IOP was  $15.4 \pm 5.5$  mmHg in the AGV group and  $13.2 \pm 6.8$  mmHg in the BGI group. The mean  $\pm$ SD number of glaucoma medications was  $1.8 \pm 1.3$  in the AGV group and  $1.5 \pm 1.4$  in the BGI group. The cumulative probability of failure in the AGV and BGI groups at 1 year were 16.4% and 14%, respectively. More patients experienced early postoperative complications in the BGI group (58%) compared to 43% in the AGV group. Serious postoperative complications also were more frequent in the BGI group than in the AGV group, at 34% versus 20%, respectively. The investigators concluded that although the average IOP after 1 year was slightly higher in patients who received an AGV, there were fewer early and serious postoperative complications associated with the use of the AGV than the BGI. This study was included in the Tseng (2017) systematic review described above.

Gedde et al. (2009) evaluated the use of the Baerveldt glaucoma implant or trabeculectomy with mitomycin C in a multicenter RCT (known as the Tube versus Trabeculectomy (TVT) Study). A total of 212 eyes of 212 patients with uncontrolled glaucoma were enrolled (tube group = 107, and 105 in the trabeculectomy group). At 3 years, IOP was 13.0 mmHg in the tube group and 13.3 mmHg in the trabeculectomy group. The number of glaucoma medications in the tube group versus trabeculectomy was 1.3 and 1.0, respectively. The cumulative probability of failure during the first 3 years of follow-up was 15.1% in the tube group and 30.7% in the trabeculectomy group ( $p = 0.010$ ; hazard ratio, 2.2; 95% confidence interval, 1.2 to 4.1). Postoperative complications developed in 39% and 60% in the tube and trabeculectomy groups, respectively ( $p = 0.004$ ). The investigators concluded that while tube shunt surgery had a higher success rate compared to trabeculectomy during the first 3 years of follow-up, both procedures were nearly equal with regard to IOP reduction and use of supplemental medication therapy at 3 years. While the incidence of postoperative complications was higher following trabeculectomy with mitomycin C (MMC) relative to tube shunt surgery, most complications were transient and self-limited. This study was included in the Tseng (2017) systematic review described above.

Mastropasqua et al. (1996) conducted a retrospective case series to evaluate long-term outcomes in patients (28 eyes) who underwent implantation of the Krupin-Denver valve for neovascular glaucoma. The preoperative IOPs ranged from 28 to 62 mmHg (mean,  $36.8 \pm 5.8$  mmHg). Success was considered an IOP of less than 22 mmHg and greater than 5 mmHg without medication (complete success) or with medication (qualified success) without additional glaucoma filtering surgery or devastating complications. Postoperative success was obtained in 10 of 28 eyes after a mean follow-up period of  $58.4 \pm 23.02$  months (range: 10-108 months). The 3- and 6-year life table success rates were 66 and 34%, respectively. Early complications included: shallow or flat AC (15 patients, 53.6%), hypotony (16 patients, 57.1%), hypertony (7 patients, 25%), serous choroidal effusion (7 patients, 25%), fibrinous uveitis (5 patients, 17.9%), blockage of the intracameral portion of the tube by fibrin (5 patients, 17.9%), choroidal hemorrhage (2 patients, 7.1%). Late complications included: external conjunctival bleb failure (12 patients, 42.9%), blockage of the intracameral portion of the tube by fibrovascular tissue (5 patients, 17.9%), cataract (2 patients, 7.1%), bullous keratopathy (2 patients, 7.1%), external erosion of the Silastic valve (2 patients, 7.1%), phthisis bulbi (2 patients, 7.1%). Mortality during long-term follow-up was high, and the complications of an underlying diabetes mellitus were the most common cause of death (15 of 22 patients). The authors concluded that the high mortality of patients subjected to valve implantation makes it difficult to interpret the results of long-term studies however, the valve implant is an alternative surgical procedure for controlling IOP in eyes with neovascular glaucoma that have visual potential. This study is limited by the lack of a comparison group.

Fellenbaum et al. (1994) conducted a single-center case series to evaluate outcomes of the patients who underwent Krupin eye valve implantation for complicated glaucomas. Medical records of 25 patients (25 eyes) were retrospectively reviewed. The authors reported that IOP was reduced from a mean of  $36.1 \pm 11.5$  mmHg to  $15.3 \pm 7.5$  mmHg at follow-up intervals of 4 to 19 months (mean, 13.2 months). On the first postoperative day, IOPs ranged from 0 to 40 mmHg. In two eyes (8%), the IOP was less than 6 mmHg, and in five eyes (20%) the IOP was more than 21 mmHg. Serous choroidal effusion and/or choroidal hemorrhage occurred in seven patients (28%). Six- and 12-month life-table success rates ( $6 \leq \text{IOP} \leq 21$  mmHg) were 84% and 66%, respectively. The authors concluded that the Krupin implant lowers IOP in most patients; however, the presence of a slit valve does not eliminate either early postoperative hypotony with its attendant complications or early IOP spikes. This study is limited by the lack of a comparison group.

The Krupin Eye Valve Filtering Surgery Study Group (1994) conducted a case series to evaluate a long posterior tube shunt device with a pressure sensitive valve for filtration surgery in eyes with recalcitrant glaucoma. One-stage implantation without the use of restrictive sutures was performed in 50 eyes with various types of glaucoma unresponsive to prior glaucoma surgery. The mean ( $\pm$ standard error of the mean) preoperative IOP of  $36.4 \pm 1.6$  mmHg was reduced



significantly ( $p < 0.001$ ) to  $8.3 \pm 1.3$  mmHg on the first postoperative day. The mean AC depth (scale, 0-4+) was  $3.4 \pm 0.1$ . The mean IOP 1 month after surgery was  $14.1 \pm 1.3$  mmHg. The implant was removed from four eyes due to IOP failure (1 eye), external erosion (2 eyes), or endophthalmitis (1 eye). A suprachoroidal hemorrhage occurred in one eye on the first postoperative day. Diplopia developed in one eye after surgery. Mean IOP at last follow-up examination (25.4  $\pm$  2.4 months; range, 16-36 months) was  $13.1 \pm 1.3$  mmHg. IOP was 19 mmHg or lower in 80% of the eyes, 59% of which were without adjunctive antiglaucoma medications. The authors concluded that this therapeutic device can be effective in the long-term control of IOP in glaucomatous eyes not responsive to prior filtration surgery with adjunctive antimetabolite therapy. This study is limited by the lack of a comparison group.

### ***XEN® Glaucoma Treatment System***

Chen et al. (2022) conducted a systematic review on XEN Gel Stents used in the treatment of OAG. 56 studies published between September 2015 and December 2021, were included in the analysis and none of them were RCTs. The authors found the XEN Gel Stent lowered IOP by approximately 35% to a final average of 15 mmHg. In addition, the number of antiglaucoma medications also showed a significant decrease. The authors concluded the XEN Gel Stent was safe and effective, but further studies should be performed to investigate the impact of ethnicity on the success and failure rate after XEN implantation since most of the patients in the analysis were Caucasian. The publication is limited by only reporting findings based on before–after measurements without comparison to groups received different treatments. This systematic review included the following studies summarized below: Tan (2021), Rauchegger (2021), De Gregorio (2018), Grover (2017), Galal (2017) and Pérez-Torregrosa (2016).

A Hayes technology assessment (2019, updated December 2021) on the XEN Glaucoma Treatment System for treatment of OAG identified 7 studies (all observational) that evaluated the safety and efficacy of the XEN treatment system. Two publications compared XEN implantation with trabeculectomy, six studies compared stand-alone XEN implantation against XEN implantation combined with cataract surgery, three publications compared XEN implantation with that of patients with POAG and patients with pseudoexfoliative glaucoma and one study assessed the use of medication between patients with prior glaucoma surgery to patients who had no prior surgical intervention. While the low-quality evidence generally resulted in positive effects for the implantation of the XEN Gel Stent, the degree of impact varied across the studies, and it was concluded that the XEN system has potential but unproven benefit.

An ECRI review, XEN Gel Stent (Allergan plc.) For Treating OAG (2021), evaluated 7 studies (1 systematic review, 2 nonrandomized comparison study, and 4 pre-post studies). It was concluded that the evidence is somewhat favorable in concluding that the XEN Gel Stent is safe and reduces IOP and the use of glaucoma medication in patients with OAG through 24 months of follow-up. The systematic review and 1 nonrandomized comparison study suggest that XEN works as well as trabeculectomy for reducing medication use and IOP in patients with OAG. One nonrandomized comparison study suggests that XEN reduces IOP and medication more than GATT; however, this study has a high risk of bias to be conclusive. Additional RCTs are still needed to validate findings, and RCTs comparing XEN with other OAG microstents would be useful. Two studies included in this review (Hengerer, 2017 and Mansouri, 2018) were also included in the Buffault (2019) systematic review.

Rauchegger et al (2021) evaluated the 2-year efficacy of XEN Gel Stent implantation in 79 eyes of patients with POAG; 23 of these patients had pseudoexfoliation glaucoma (XFG). The primary outcome of the study was mean reduction in IOP along with a decrease in medication usage. Participants were evaluated preoperatively and day one postoperatively in addition to evaluations at 1 week and then every month up to 2 years. Overall, 28% of the patients completed postop visits through the 24-month follow-up. Needling was documented in 62% of the patients as an additional postoperative treatment to improve aqueous flow and lower IOP. Thirteen eyes needed a glaucoma-related secondary surgical intervention and therefore were considered complete surgical failures. The most common AE was hyphema which occurred in 5 patients and self-resolved within 7 days. The authors saw a meaningful drop of IOP from  $23.4 \pm 7.9$  mmHg preoperatively to  $14.6 \pm 3.6$  mmHg at month 12 and  $14.8 \pm 4.4$  mmHg at month 24 postoperatively. The results suggest the XEN Gel Stent significantly reduces the patient's IOP over a 2-year period. The findings are limited by the retrospective nature of the study, lack of comparison group and the low number of patients being seen at 24-months, but the authors contributed this to the number of patients that completed their follow-up with private practice ophthalmologists.

Tan et al. (2021) compared the safety and efficacy of two different techniques for implantation of the XEN Gel Stent. The chart review analyzed fifty eyes that underwent the ab interno placement and 30 eyes which underwent the ab externo placement. The cohort that received the ab interno procedure demonstrated a mean IOP reduction of  $8.4 \pm 1.7$  mmHg by 12 months; the ab externo group underwent a mean reduction of  $12.8 \pm 3.0$  mmHg. Average medications reduction in the ab interno group was  $1.81 \pm 0.29$  and in the ab externo group was  $1.86 \pm 0.37$ . No statistically significant differences were found in IOP control, medication reduction, or AEs. The authors concluded there were no differences in outcomes between the two procedures and the insertion of the XEN Gel Stent. Limitations included retrospective review, lack of



comparison group receiving treatments other than the XEN Gel Stent, small sample size, lack of long-term data beyond one year and differences in technique proficiency amongst surgeons.

Buffault et al. (2019) conducted a systematic review to analyze the change in IOP and glaucoma medications using the XEN<sup>®</sup> Gel Stent as a solo procedure or in association with phacoemulsification in patients with chronic OAG. Using predetermined search terms, a systematic review was performed using PubMed. A total of 8 case series or cohort studies (6 prospective and 2 retrospective) that were published between 2016 and 2018, were included. There were no randomized controlled trials included. Data was analyzed for 777 patients or 958 eyes. The various studies showed a mean IOP at 12 months between 13 and 16 mmHg, which represented an IOP reduction between 25 and 56% (mean: 42%). This decrease was associated with a reduction in glaucoma medications in all studies. The decrease in IOP was significantly greater in XEN<sup>®</sup> implantation as a stand-alone procedure (44%) than in combined surgery (32%) ( $p < 0.05$ ). Transient hypotony ( $< 1$  month) (3%), choroidal detachment or choroidal folds (1.5%), hyphema (1.9%), bleb leak (1.1%) and shallow AC (1.1%) were the most frequent complications. As for severe complications, four cases of malignant glaucoma (0.4%) and one case of retinal detachment have been reported. In the follow-up period, needling was being required in 32% of cases, and a total of 55 eyes (5.7%) required repeat filtering surgery or cyclodestructive procedure. The authors concluded that the XEN<sup>®</sup> Gel Stent appears effective for reducing IOP and the number of medications in OAG patients within 1 year postoperatively, and with an acceptable safety profile. However, its use required vigilant postoperative follow-up and frequent postoperative interventions. While these results appear promising, randomized controlled trials are needed to confirm the XEN<sup>®</sup> Gel Stent's safety and efficacy.

De Gregorio et al. (2018) conducted a nonrandomized prospective clinical study to assess safety and efficacy of the XEN<sup>®</sup> 45 Gel Stent when combined with microincisional cataract surgery (MICS). Forty-one eyes of 33 patients with OAG underwent the combination surgery, and there were no major intra- or post-operative complications noted. Complete success was achieved in 80.4% and a qualified success reported in 97.5% after 12 months of follow-up. The authors concluded that the XEN<sup>®</sup> 45 gel implant is statistically effective in reducing IOP and medication use with minimal complications in glaucoma patients. The finding is limited by the lack of a comparison group. This study was included in the Buffault (2019) study.

Schlenker et al. (2017) conducted an investigator-initiated, international, multicenter, retrospective cohort study of consecutive patients who underwent either standalone microstent insertion (XEN 45 microstent) with mitomycin C (MMC) or trabeculectomy with MMC. A total of 354 eyes of 293 patients (185 microstent and 169 trabeculectomy) participated in the study that extended between January 1, 2011, and July 31, 2015. Eligibility criteria included patients with multiple types of glaucoma and above-target IOP on maximum medical therapy. Participants were between the ages of 30-90 years with no history of previous incisional surgery for their eye disease. The authors concluded that there was no detectable difference in risk of failure and safety between standalone microstent with MMC and trabeculectomy with MMC. As with any retrospective cohort studies, the risk for bias is elevated. Further research was believed to be warranted to further investigate these procedures. This study was included in the Buffault (2019) study.

Galal et al. (2017) conducted a prospective interventional case series of 13 eyes with POAG underwent XEN<sup>®</sup> implantation with subconjunctival mitomycin-C. Of those eyes, 3 were pseudophakic and 10 underwent simultaneous phacoemulsification and XEN. Patients had uncontrolled IOP, intolerance to therapy, or maximal therapy but undergoing cataract extraction. One year of follow-up documentation of IOP, number of medications, visual acuity, and complications. Complete success was defined as IOP reduction  $\geq 20\%$  from preoperative baseline at 1 year without any glaucoma medications, while partial success as IOP reduction of  $\geq 20\%$  with medications. Results reflected a drop in IOP from  $16 \pm 4$  mmHg pre-op to  $9 \pm 5$ ,  $11 \pm 6$ ,  $12 \pm 5$ ,  $12 \pm 4$ , and  $12 \pm 3$  mmHg at 1 week, 1, 3, 6, and 12 months, respectively. At 1 year, (BCVA improved from  $0.33 \pm 0.34$  to  $0.13 \pm 0.11$ ; and mean number of medications decreased from  $1.9 \pm 1$  preoperatively to  $0.3 \pm 0.49$ . 42% of eyes achieved complete success and 66% qualified success. Complications included choroidal detachment in 2 eyes, implant extrusion in 1 eye, and 2 eyes underwent trabeculectomy. The authors concluded that the XEN implant is an effective surgical treatment for POAG, with significant reduction in IOP and glaucoma medications at 1 year, and state that longer follow-up is needed. The findings are limited by the lack of a comparison group. This study was included in the Buffault (2019) study.

Grover et al. (2017b) evaluated the performance and safety of the XEN<sup>®</sup> 45 Gel Stent (Allergan, Irvine, CA) for the treatment of refractory glaucoma in a prospective, single-arm, open-label, multicenter case series sponsored by the manufacturer. Selection criteria included individuals with refractory glaucoma, defined as prior failure of a filtering or cilioablative procedure and/or uncontrolled IOP on maximally tolerated medical therapy. A total of 65 eyes in patients 45 years of age and older were implanted. No intraoperative complications or unexpected postoperative AEs were reported. During the 1 year of follow up, most AEs were considered mild/moderate and resolved with no sequelae. The authors concluded that the XEN<sup>®</sup> 45 Gel Stent safely reduced both IOP and medication use and offer a less invasive surgical

option for this subset of patients. Potential study limitations include the absence of comparator and open-label study design, which could have impacted the outcomes.

To assess the safety and efficacy of phacoemulsification combined with XEN<sup>®</sup> 45 implant surgery, a prospective case series (Pérez-Torregrosa et al., 2016) was conducted on 30 eyes of patients with cataract and OAG. Surgery was performed using 2 temporal incisions within 15 minutes of administering subconjunctival mitomycin C. Outcomes measured were BCVA, IOP before and 1 day, 1 month, 3 months, 6 months, 9 months, and 12 months after surgery, number of anti-glaucoma medications, and AEs. BCVA before and 12 months post-surgery was 0.37 ±0.2 and 0.72 ±0.15, respectively. The pre-operative IOP was 21.2 ±3.4mmHg, with 3.07 drugs, decreasing by 61.65% on the first day, 37.26% at 1 month, 35.05% at 3 months, 31% at 6 months, 30.6% at 9 months, and 29.34% at 12 months. Anti-glaucoma medication usage decreased by 94.57%. Complications occurred in 3 eyes: 2 of them were excluded because the implantation could not be completed, and 1 developed an encapsulated bleb at 5 months post-surgery. The authors concluded that phacoemulsification combined with XEN<sup>®</sup> 45 implant surgery can effectively reduce IOP and the number of drugs in mild-moderate OAG with few complications. The findings are limited by the lack of a comparison group. This study was included in the Buffault (2019) study.

## **Canaloplasty (Ab Interno)**

There is insufficient quality evidence in the published clinical literature to determine the safety and efficacy of canaloplasty using an ab interno approach for the treatment of glaucoma.

A Hayes Health Technology Assessment, Canaloplasty for Open-Angle Glaucoma (2020, updated January 2022), states that there is insufficient evidence to assess the effectiveness and safety of ab interno canaloplasty.

Ondrejka and Körber (2019) conducted a retrospective case series of 106 eyes from 71 patients with mild to moderate POAG that underwent ab-interno canal viscodilation with the VISCO360 device. Patients were divided into two groups; group 1 had 72 eyes with a baseline IOP ≥ 18 mmHg and group 2 had 34 eyes with baseline IOP of < 18 mmHg. Twelve eyes received standalone ab-interno canal viscodilation (VISCO360-alone) and 94 eyes received ab-interno canal viscodilation in conjunction with cataract extraction (CE) (VISCO360+CE). Primary outcomes measured were the change in mean IOP and the mean number of IOP-lowering medications. Postoperatively, patients received topical tobramycin/dexamethasone medication five times each day for 1 week; then patients received dexamethasone drops four times daily for the second week. All patients had their fundus and anterior angle assessed and were evaluated for best corrected visual acuity, IOP, and medications. Follow up visits occurred on postop day 1, at one month, 3 months and then every 3 months thereafter. At 12 months, group 1 mean IOP reduced from 24.6 ±7.1 mmHg to 14.6 ±2.8 mmHg; group 2 had a mean IOP of 14.9 ±1.8 mmHg at baseline and at 12 months showed no significant difference with a mean IOP at 13.6 ±2.3 mmHg. The authors found that microcatheterization and viscodilation of SC with the VISCO360 Viscosurgical System with or without CE can be safely and consistently performed in patients with mild-moderate POAG. Limitations included lack of comparison group undergoing a different treatment approach, small sample size, lack of long-term effectiveness beyond a year.

Gallardo et al. (2018a) conducted a retrospective single-center case series of patients with uncontrolled POAG who underwent ab-interno canaloplasty (ABiC) as a stand-alone procedure or in conjunction with cataract extraction. The primary outcomes were mean IOP and mean number of glaucoma medications. Secondary outcomes included surgical and postsurgical complications and secondary interventions. A subset analysis was conducted comparing the outcomes of patients who underwent ABiC and phacoemulsification vs. ABiC as a stand-alone procedure. A total of 68 patients (75 eyes) were included with a mean age of 73.7 ±9.9 years. At baseline, the mean IOP was 20.4 ±4.7 mmHg and mean medication use was 2.8 ±0.9. Twelve months postoperatively, the mean IOP reduced to 13.3 ±1.9 mmHg (n = 73) and mean medication use was reduced to 1.1 ±1.1 medications. At 12 months, 40% of eyes were medication free. In the ABiC/phacoemulsification subgroup (n = 34 eyes), the mean IOP and medication use decreased from 19.4 ±3.7 mmHg on 2.6 ±1.0 medications preoperatively to 13.0 ±1.8 mmHg on 0.8 ±0.2 medications at 12 months (both p < 0.001). In the stand-alone ABiC subgroup (n = 41), the mean IOP and medication use decreased from 21.2 ±5.3 mmHg on 3.0 ±0.7 medications preoperatively to 13.7 ±1.9 mmHg on 1.3 ±1.1 medications at 12 months (p = 0.001 and p < 0.001, respectively). No serious AEs were recorded. The authors concluded that their results demonstrate that ABiC was effective at reducing IOP and medication use in eyes with uncontrolled POAG with or without cataract surgery. However, limitations of this study should be noted. For example, all cases are from a single center, the study design, as a retrospective case series, is uncontrolled and subject to selection bias, the combination cataract surgery results are confounded by the IOP-lowering effect of cataract surgery and therefore, the precise mechanism of the ability of ABiC to reduce IOP is unclear, and only 12 months of follow-up. Longer-term, multi-center prospective randomized trials with a larger sample size are still needed to assess the safety and efficacy of ABiC.

Gallardo et al. (2018b) conducted a non-randomized, retrospective, single-center paired eye cohort study to assess the efficacy of ABiC vs. ab-externo canaloplasty (CP) in reducing IOP and glaucoma medication dependence. Patients with POAG underwent ABiC in one eye and CP in the other eye, either as stand-alone procedures or combined with cataract extraction. The primary outcomes included mean IOP and number of glaucoma medications at 12 months after surgery. Secondary outcomes included surgical complications and secondary interventions. A total of 12 patients (8 females and 4 males) with a mean age of  $73.8 \pm 12.6$  years were included. In the CP group, the mean preoperative IOP was  $18.1 \pm 3.9$  mmHg on  $2.4 \pm 0.5$  medications, which reduced to  $13.5 \pm 2.2$  mmHg ( $p < 0.05$ ) on  $0.9 \pm 0.9$  medications ( $p < 0.001$ ). In the ABiC group, the mean preoperative IOP was  $18.5 \pm 3.4$  mmHg on  $2.4 \pm 0.5$  medications and postoperative IOP was  $13.8 \pm 2.2$  mmHg ( $p < 0.05$ ) on  $0.8 \pm 0.8$  medications ( $p < 0.05$ ). There was no significant difference in IOP, and medication use between treatment groups at 12 months after surgery. No serious AEs were recorded in either group, though two patients in the CP group developed pressure spikes 10 mmHg beyond preoperative IOP. The authors concluded that in this small pilot paired eye study, ABiC was found to have comparable IOP lowering and glaucoma medication reduction to CP in OAG and that ABiC may be a suitable method for improving aqueous outflow via the trabecular pathway. Limitations of this study include lack of randomization and small sample size that may have been insufficient to detect clinically significant differences.

## **Combined Canaloplasty (Ab Interno) and Gonioscopy-Assisted Transluminal Trabeculotomy**

There is insufficient quality evidence in the published clinical literature to determine the safety and efficacy of combined canaloplasty (ab interno) and gonioscopy-assisted transluminal trabeculotomy (GATT) for treatment of glaucoma e.g., with the OMNI surgical system.

In 2022, Toneatto et al. evaluated the effectiveness of ab-interno microcatheterization and 360 degrees viscodilation of SC performed with the OMNI surgical system in 73 patients with OAG. A total of 80 eyes were assessed and divided into two groups. Group 1 had 50 eyes that underwent ab interno microcatheterization and SC viscodilation, while 30 eyes in group 2 underwent glaucoma surgery + cataract extraction. Preoperatively each patient underwent a complete baseline ophthalmologic examination and IOP was measured by the Goldmann applanation tonometry. The main primary outcome was defined as a reduction in IOP equal to or greater than 25% from baseline at the 12-month follow-up visit; and the eyes that reached this goal without any medical treatment were considered a complete success. Baseline IOP for all eyes had an average of  $22.5 \pm 5.3$  mmHg. The authors found after 12 months the mean IOP was reduced to  $15.0 \pm 3.6$  mmHg which was statistically significant. However, the reduction in medications at 12 months was not significantly significant between the two groups; the average for groups 1 and 2 were  $3.0 \pm 1.1$  and  $3.4 \pm 0.8$ , respectively, and at 12 months decreased to  $2.0 \pm 1.4$  and  $1.9 \pm 1.4$ , respectively. The authors found approximately 15% of eyes achieved an IOP of 18 mmHg or lower with no medications and an overall success rate of 71.8%. The authors concluded that SC viscodilation with the OMNI device appears to be promising at controlling IOP, however, further studies are needed to report long-term outcomes and complications. Limitations included lack of comparison to other glaucoma treatments, small sample size, lack of long-term outcomes and retrospective design.

An ECRI review, Omni Surgical System (Sight Sciences, Inc.) for Treating OGA, evaluated 3 studies (4 publications), which reported on a total of 217 patients. Those included case series, 3 retrospective and 1 prospective. It was concluded that very-low-quality evidence suggest that the OMNI Surgical System is safe and reduces IOP and medication use up to 18 months of follow-up in patients with mild to moderate OAG when performed alone or during cataract surgery. No studies compared OMNI with other OAG treatments. RCTs comparing OMNI with other MIGSs and with long-term (> 12 months) outcomes are still needed to assess its safety and effectiveness (2021). This ECRI report includes the review of the studies by Hughes and Traynor (2020), Vold, et al (2021) and Hirsch et al (2021).

Gallardo et al. (2021) conducted a multicenter case series to report 6-month safety and efficacy outcomes of 360° canaloplasty and 180° trabeculotomy using the OMNI® Surgical System concomitantly with phacoemulsification in patients with open-angle glaucoma (OAG). Eligible patients had cataract and mild-moderate OAG with IOP  $\leq 33$  mmHg on 1 to 4 hypotensive medications. Effectiveness outcomes included mean IOP and medications. Safety outcomes included AEs, best corrected visual acuity (BCVA) and secondary surgical interventions (SSI). A total of 137 patients were enrolled and treated. Mean diurnal IOP after washout was  $23.8 \pm 3.1$  mmHg at baseline. At month 6, 78% (104/134) of patients were medication free with IOP of 14.2 mmHg, a mean reduction of 9.0 mmHg (38%). One hundred percent (104/104) had a  $\geq 20\%$  reduction in IOP and 86% (89/104) had IOP  $\geq 6$  and  $\leq 18$  mmHg. The mean number of medications at screening was  $1.8 \pm 0.9$  and  $0.6 \pm 1.0$  at month 6. AE included transient hyphema (4.6%) and IOP elevation  $\geq 10$  mmHg (2%). There were no AEs for loss of BCVA or recurring hyphema. There were no SSI. The authors concluded that canaloplasty followed with trabeculotomy and performed concomitantly with phacoemulsification has favorable intra and perioperative safety, significantly reduces IOP and anti-glaucoma medications through 6 months in eyes with mild-moderate OAG. Limitations of this study include its design, which lacks a comparison group and short follow-up period. Additional prospective,



randomized studies are still needed to determine the efficacy and safety of this technology. A 2022 update by Gallardo et al. reported on the 12-month efficacy outcomes using the OMNI surgical system in combination with phacoemulsification in patients with mild-moderate OAG and cataracts. At month 12, 84.2% of eyes achieved IOP reductions > 20% from baseline, 80% of eyes were medication-free, and 76% of eyes achieved IOP between 6-18 mmHg inclusive. AEs were uncommon, mild and self-limited including transient hyphema and transient IOP elevations. The authors concluded the OMNI surgical system at the time of phacoemulsification significantly reduces unmedicated mean diurnal IOP and medication use 12 months postoperatively, with an excellent safety profile. Limitations of this study include a lack of control group or comparison of OMNI to other procedures.

Grabska-Liberek et al. (2021) conducted a case series study to characterize clinical outcomes of combined viscodilation of SC and collector channels and 360° trabeculotomy using the OMNI surgical system as a standalone procedure or combined with cataract surgery in eyes with mild to moderate OAG. Eligible participants were adults aged 45 years or older, with either visually significant cataract or pseudophakia, and OAG (including primary, pigmentary, and pseudoexfoliative) with IOP > 21 mmHg using up to three topical IOP-lowering medications. The primary outcome was the proportion of eyes with IOP reduction ≥ 20% from baseline using the same number or fewer IOP-lowering medications compared to baseline at Month 24. Secondary outcomes included the proportion of eyes with IOP ≤ 18 mmHg and the proportion with IOP ≤ 15 mmHg (and IOP ≥ 6 mmHg in both cases) at Month 12; the proportion of eyes that were medication-free or on at least one fewer medication compared to baseline at Month 12; changes from baseline in IOP and the number of IOP-lowering medications at each visit; and the number of secondary surgical interventions performed for IOP control. Safety endpoints included the nature and incidence of ocular AEs. Participants were re-evaluated at 1 week and 1, 3, 6, 12, and 24 months postoperatively. Among 17 eyes of 15 subjects, mean IOP was reduced from 20.4 mmHg to 12.7–13.7 mmHg through 12 months of follow-up ( $p < 0.001$  at every time point) and mean medications reduced from 2.5 to 0.1–0.6 ( $p < 0.001$  at every time point). IOP reductions in eyes undergoing standalone surgery were approximately 2–4 mmHg greater at each time point compared to eyes undergoing surgery combined with phacoemulsification; this may be related to a higher baseline IOP in the former eyes (22.1 vs. 18.5 mmHg). Six eyes developed hyphema, of which three required wash-out for elevated IOP on the first postoperative day; six additional eyes had IOP elevations that resolved with medical management. The authors concluded that viscodilation of SC and collector channels paired with ab interno trabeculotomy performed with a single integrated instrument (OMNI), whether as standalone or combined with phacoemulsification, effectively lowers both IOP and the need for IOP-lowering medications through 12 months of follow-up. The authors also mentioned that this study ongoing and 24-month data will be reported when available. Limitations of this study include its design, a case series lacking a contemporaneous comparison group, the small sample size, that all surgeries were performed by the same surgeon, and the unexpectedly high rate of hyphema. Additional randomized studies with larger sample sizes and longer follow-up periods are still needed to clarify efficacy and safety of this technology.

Klabe and Kaymak (2021) analyzed a case series of 27 patients that were approximately 67 years of age and underwent 360° viscodilation followed by up to 360° trabeculotomy as a standalone procedure. The primary goal of this analysis was to distinguish changes in IOP and IOP medication. 38 eyes underwent the surgical procedure; 30 eyes were available for analysis at one year; and 26 eyes were available for analysis at 2 years. The authors found at 24 months 88.5% (23/26) of eyes had shown an IOP below 18 mmHg: 14 (61%) of these without medication. In addition, 84.6% of eyes were using at least 1 less medication than at baseline, and 57.7% were medication-free. AEs included transient postoperative hyphema in 17 eyes; other AE included choroidal effusion, anterior synechiae, and transient lens-cornea touch associated with shallow AC. Limitations included study design, which was retrospective in nature and lacked a comparison group.

Pfyfer et al. (2021) conducted a 12-month case series from the GEMINI study [Gallardo (2021)]. The OMNI device was used following phacoemulsification to perform a sequential ab interno canaloplasty followed by a trabeculotomy on 128 patients with OAG. IOP was measured at 9 AM ( $\pm 1.5$  hours), 12 PM ( $\pm 1$  hour), and 4 PM ( $\pm 2$  hours) using Goldmann applanation tonometry. Two measurements were taken from each eye with the mean value recorded as the IOP for that time point. Measurements were taken again at 12 months. The authors found 95% of patients experienced an overall reduction in IOP; 91% of the patients experienced an IOP reduction of at least 3 mmHg and 86% of patients experienced a reduction in IOP of at least 20%. It was concluded that patients with OAG can benefit from overall decrease IOP for 12 months after surgical treatment. Limitations included lack of comparison group and the inability to generalize the assessment to other minimally invasive glaucoma surgery procedures and implants.

## **Glaucoma Drainage Devices Not Approved by the U.S. Food and Drug Administration (FDA)**

There is insufficient quality evidence in the published clinical literature to determine the safety and efficacy of the Eyepass and SOLX Gold Shunt for the treatment of glaucoma.



## ***Eyepass***

Wittmann et al. (2017) conducted a prospective case series evaluation of patients with OAG who underwent an implantation of the Y-shaped Eyepass glaucoma implant. The outcomes of interest were IOP, visual acuity, complications and the number of anti-glaucomatous medications were during a period of 5 years. A total of 15 patients (16 eyes) POAG underwent implantation of the Y-shaped Eyepass glaucoma implant. Mean IOP was reduced from 26.4 ±8.1 mmHg (SD) to 16.4 ±5.3 mmHg ( $p = 0.032$ ) at the end of the follow-up. Mean number of anti-glaucomatous medications dropped from 2.1 ±1.2 (SD) to 0.9 ±1.2 (SD). In 5 cases, no pressure-lowering medications were necessary 5 years after surgery. Mean best-corrected visual acuity did not change significantly ( $p > 0.05$ ). In all cases, filtering blebs were observed and sustained using antimetabolites. The most common complication was temporary ocular hypotony. Two patients required a revision surgery due to implant malposition. The authors concluded that the Eyepass glaucoma implant seems to be a safe and effective treatment option for patients with POAG. While these results are promising, FDA approval and randomized controlled trials with comparisons to other glaucoma implants are still needed.

Dietlein et al. (2008) conducted a pilot case series study to evaluate the safety and pressure-reducing efficacy of the Y-shaped Eyepass glaucoma implant in 12 glaucoma and cataract patients, finding that combined cataract surgery with Eyepass shunt implantation was safe and appeared to be beneficial in glaucomatous eyes with cataract not requiring a low target IOP. Perforation of the trabecular meshwork during Eyepass implantation occurred in 2 eyes requiring explanation. In the remaining 10 eyes, the mean maximum IOP was 30.4 mmHg preoperatively, 12.0 mm 1 day postoperatively, 17.2 mmHg at 4 weeks, and 18.3 mm at the end of the preliminary follow-up. FDA approval of the Eyepass glaucoma implant and randomized controlled studies with long-term results are still needed to determine its safety and efficacy.

## ***SOLX Gold Shunt***

Tanito and Chihara (2017) conducted a case series to assess the safety and effectiveness of the SOLX gold shunt (GS) in reducing IOP in Japanese patients with OAG. Best-corrected visual acuity (BCVA), IOP, corneal endothelial cell density (CECD), AC flare, surgical complications, and required interventions were monitored at baseline, and 1 day, 1 week, 1, 3 and 6 months, and 1 year postoperatively. A total of 24 patients (24 eyes) were implanted with the GS either with or without cataract surgery. The mean age was 68.9 ±12.7 years, 67% were women, 29% were diagnosed with pseudoexfoliation glaucoma and 1 had steroid response glaucoma. Baseline IOP of 21.3 ±4.1 mmHg and glaucoma medications of 3.5 ±1.0 were significantly reduced at every follow-up visit. At 1 year postoperatively, IOP was 16.4 ±5.8 mmHg (23% reduction from baseline,  $p < 0.0001$ ) with use of 2.1 ±1.1 medications (40% reduction from baseline,  $p = 0.0002$ ). Intraoperative hyphema occurred in 5 (21%) eyes. Transient bleb formation occurred in 20 (83%) eyes, and AC cell was reported in 17 (71%) eyes. Inflammation-related complications such as posterior and anterior synechiae or iritis/keratic precipitates tended to occur during late postoperative periods. At 1 year, BCVA was unchanged or improved in 23 (96%) eyes. AC flare was elevated at 1 week postoperatively and later. CECD declined at 3 months and 1 year postoperatively. The authors concluded that GS is effective in reducing IOP in Japanese patients with OAG and that chronic inflammation in AC might be associated with late onset complications. FDA approval of the SOLX gold shunt and randomized controlled trials with long-term follow-up and comparisons to other glaucoma implants are still needed to determine its safety and efficacy.

One Phase III trial has been completed, but no data has yet been published  
<http://clinicaltrials.gov/ct2/show/NCT01282346>. (Accessed February 16, 2023).

## **Goniotomy or Gonioscopy-Assisted Transluminal Trabeculotomy - For All Other Indications**

There is insufficient quality evidence in the published clinical literature to determine the safety and efficacy of goniotomy or gonioscopy-assisted transluminal trabeculotomy (GATT) for all other glaucoma types except pediatric glaucoma. RCTs comparing goniotomy or gonioscopy-assisted transluminal trabeculotomy (GATT) to usual care or other glaucoma surgeries provide conflicting results: Ventura-Abreu et al. (2021), Falkenberry et al. (2020)

Aktas et al. (2021) evaluated a retrospective case series of 15 patients with SOAG for long-term effects following GATT. These patients were enrolled between May 2014 and May 2019, at Gazi University Hospital for the treatment of medically uncontrolled SOAG after silicone oil (SO) removal. Baseline evaluation for all patients included a detailed ophthalmic examination and Goldmann applanation tonometry. Surgical success was defined as an IOP ≤ 21 and ≥ 6 mmHg. Postop visits were conducted the day after surgery, and then data was collected at first week, first month, third month and every 3 months. The authors concluded that GATT seems to be effective since the results showed a final mean IOP of 15.6 ±4.6 mmHg, however the need for medication did increase over the follow-up period. Limitations included lack of comparison group undergoing a different treatment approach, retrospective design and small sample size.

Belkin et al. (2021) conducted a retrospective case series study to report the efficacy and safety of GATT in patients with uveitic glaucoma. Thirty-three eyes of 32 patients were included with a mean patient age of  $49 \pm 16$  years. The data was collected through chart review and communication with eye health professionals involved in patient follow-up. Primary outcome was a reduction in IOP  $\leq 18$  mmHg and one of the following: IOP within one mmHg of baseline on fewer glaucoma medications as compared with baseline or a 30% IOP reduction from baseline on the same or fewer glaucoma medications. After review and analysis of the data, the authors found a 72% success rate. Limitations should be considered when evaluating these results. For example, the retrospective case series design lacks randomization or comparisons to other glaucoma surgical procedures; in addition, the sample size was small and lacked long-term outcomes.

A 2021 ECRI clinical evidence assessment of the Trabectome an electrosurgical platform intended to reduce IOP in patients with glaucoma. It includes a single-use handpiece with an electrode tip, an irrigation/aspiration unit, and a separately sold high-frequency generator. Using microscope visualization, an ophthalmic surgeon inserts the handpiece's tip via a small corneal incision, using continuous irrigation. The surgeon uses the electrode tip to ablate the trabecular meshwork, guiding it along the SC, up to  $90^\circ$  to the left and right of the incision. Trabectome can be performed alone or in combination with cataract surgery. The report concluded low-quality evidence from 2 systematic reviews and 6 additional nonrandomized comparison studies. Three other nonrandomized comparison studies are too high risk of bias to determine how well Trabectome works compared with ab externo trabeculectomy. Additional randomized controlled trials comparing Trabectome with MIGs are needed to validate findings. Evidence limitations include high risk of bias, small study size, retrospective design, single-center focus and lack of randomization and blinding.

Hu et al. (2021) conducted a search of the (CENTRAL), Ovid MEDLINE, Ovid Embase, the ISRCTN registry, ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) for RCTs of ab interno trabecular bypass surgery with the Trabectome procedure when compared to other MIGs, laser or medical treatment. The authors found no high-quality evidence to determine whether ab interno trabecular bypass surgery with the Trabectome procedure for open-angle glaucoma was better or worse than conventional surgery. It was concluded properly designed RCTs are needed to assess the long-term efficacy and safety of this technique.

Sharkawi et al. (2021) reported on outcomes from a non-comparative prospective case series of 103 eyes from 84 patients with pseudoexfoliative glaucoma. The patients underwent a 360-degree ab interno trabeculotomy procedure with gonioscopic assistance. Primary outcomes were IOP and the number of glaucoma medications. Combined cataract surgery with GATT was performed in 50 eyes while the other 53 eyes were already pseudophakic. The complication rate was minimal at 2.9% with only one patient experiencing transient hypertony. The combination of cataract surgery and GATT maintained the same effectiveness as GATT alone in pseudophakic patients. Postoperatively, IOP was reduced by 52%. The authors concluded the study demonstrated that GATT safely and effectively lowers IOP in PXG, whether performed alone or in addition to cataract surgery. Limitations included absence of a comparative group and lack of long-term outcomes.

A single-center longitudinal RCT was conducted by Ventura-Abreu et al. (2021) to evaluate the efficacy and safety of the KDB ab interno trabeculectomy combined with phacoemulsification (phaco) compared to stand-alone conventional cataract surgery. Forty-two eyes from 33 patients over the age of 18 years were randomly allocated to the combined cataract and KDB treatment ( $n = 21$ ) or cataract alone ( $n = 21$ ) groups. Preoperative and postoperative data were collected and analyzed at 1-, 3-, 6-, and 12-months post procedure. IOP decreased from  $17.9 \pm 3.5$  to  $16.0 \pm 2.2$  mmHg and from  $17.3 \pm 2.5$  to  $15 \pm 3.2$  mmHg at the last visit in the treatment and control groups ( $p = 0.47$ ). The use of glaucoma medications was reduced from a median (IQR) 1 (1–2) to 0 (0–0) in the treatment group and from 1 (1–2) to 0 (0–1) in the control group, with no significant differences between groups at the 12-month visit ( $p = 0.47$ ). The authors concluded the KDB ab interno trabeculectomy along with cataract surgery might not offer additional IOP and glaucoma medications reduction compared to stand-alone phacoemulsification. There were no significant major complications found for safety, however there was one case of corneal decompensation in the treatment group. Limitations in the study include small sample size, which could have been too small to detect clinically significant differences, and lack of investigation of systematic medications and medication wash-out.

A systematic review and meta-analysis by Guo et al. (2020) of ten studies evaluated the safety and efficacy of GATT in patients with open angle glaucoma; one study was not pooled for the meta-analysis due to a repeat in data. All studies were case series without a comparison group undergoing a different treatment. The primary outcome was a decrease of IOP and the authors found most patients following the surgery still needed anti-glaucoma medication, but the pooled results showed a significant decrease in medications. The most common complication seen was hyphema which was observed in all the studies. Limitations included lack of comparison group, variances amongst the studies including baseline IOP, patient follow up and primary diseases that could have impacted the results. While the authors identified that GATT could effectively lower IOP and decrease medications overall, they agreed RCTs with larger sample sizes

should be conducted before drawing any final conclusions. (Rahmatnejad et al. 2017 and Grover et al. 2017a, previously cited in this policy is included in this meta-analysis).

A 2020 ECRI health technology assessment report of the KDB evaluates the safety and effectiveness for the standalone procedure to treat glaucoma. The Kahook Dual Blade is a sterile, single-use ophthalmic knife for minimally invasive excisional goniotomy procedures to treat glaucoma by removing part of the trabecular meshwork to improve eye fluid flow into the SC and reduce IOP. Four retrospective case series reported on IOP, medication use, visual acuity and AEs. The report concluded the evidence of this device is inconclusive. Further RCTs comparing KDG with other glaucoma treatments are needed to address evidence gaps. Evidence limitations include high risk of bias due to single-center focus, small study size, short term follow-up, retrospective design, patient bias and lack of controls.

Falkenberry et al. (2020) conducted a multicenter prospective RCT to compare reduction in IOP and IOP-lowering medication in eyes undergoing excisional goniotomy with KDB versus iStent (first generation) implantation both combined with phaco in eyes with mild to moderate OAG. The study included 164 eyes of 164 patients randomized to analyze visual acuity, IOP, IOP lowering medications and AEs postoperatively on day 1, week 1, and months 1, 3, 6, and 12. The primary outcome stated in clinicaltrials.gov was percent reduction in mean IOP at 12 months, but in the publication was the proportion of eyes at 12 months with IOP reduction of 20% or greater or IOP medication of 1 or more compared with baseline. The results showed the composite outcome was attained in 74 (93.7%) of 79 patients of KDB eyes and 65 (83.3%) of 78 patients of the iStent eyes ( $p = .04$ ). As this outcome was not listed a priori in clinicaltrials.gov, these findings should be considered as resulting from post hoc analyses and should be taken cautiously. The mean percentage IOP reductions from 1 month onward were not significantly different at any point after day 1. The mean post-operative medications were not statistically different between groups beginning at 1 month. The most common AEs in the KDB-Phaco groups and iStent-Phaco groups were increase IOP occurring in 31.7% (KDB) eyes and 33.3% (iStent) eyes, posterior capsule opacification in 8.5% (KDB) and 6% (iStent), and hyphema in 3.7% (KDB) and 1.2% (iStent) of eyes. The authors concluded both procedures lowered both IOP and the need for IOP lower medications. Significantly, more KDB-Phaco eyes than iStent-Phaco eyes met the primary outcome of 20% or greater IOP reduction or more than 1 medication reduction at 12 months. However, the mean IOP and medication reductions seen in the KDB-Phaco group in this study (approximately 17% and 80%) are likely the result of more eyes undergoing surgery with the goal of medication reduction rather than IOP reduction, as evidenced by the relatively low baseline IOP of the eyes in the KDB-Phaco group. Limitations in the study include relatively small sample size, study not designed to test for non-inferiority, lack of masking, which could have impacted the number of medications ordered, no long-term outcomes, and possible conflict of interest in a manufacturer sponsored study.

A 2019 retrospective cohort study by ElMallah et al. analyzed the efficacy and safety of combined cataract extraction with excisional goniotomy performed with the KDB (KDB; phaco-KDB group) compared to the single iStent trabecular bypass implantation (phaco-iStent group) in eyes with mild to moderate glaucoma and visually significant cataract. The study included 315 eyes from 230 adults treated with one or more IOP-lowering medications (190 eyes in phaco-KDB group and 125 eyes in the phaco-iStent group) that required no subsequent surgical intervention for IOP control through 12 months. Data included visual acuity, IOP and IOP-lowering medications preoperatively and postoperatively at week 1 and month 1, 3, 6, and 12 as well as AEs. The primary outcome was the proportion of subjects achieving  $\geq 20\%$  IOP reduction and  $\geq 1$  medication reduction at month 12. The results showed at month 12, IOP reductions  $\geq 20\%$  were achieved by 64.2% and 41.6% ( $p < 0.001$ ) in the phaco-KDB and phaco-iStent groups, and IOP medication reductions of  $\geq 1$  medication were achieved by 80.4% and 77.4% ( $p = 0.522$ ). However, baseline IOP was significantly higher in the phaco-KDB group compared with the phaco-iStent group [18.2 (0.3) vs. 16.7 (0.3) mmHg,  $p = 0.001$ ]. AEs included transient IOP elevations, transient AC inflammation, corneal edema, and posterior capsule opacification. Transient blood reflux was seen in 38 eyes in the phaco-KDB group (19.8%) and in 5 eyes in the phaco-iStent group (4%). The authors concluded statistically significant mean IOP and mean IOP medication reductions from baseline were achieved at all time points in both groups. Limitations in the study include study design, small sample size, lack of randomization of treatment groups, short-term outcomes and possible conflict of interest in manufacturer sponsored study. Furthermore, significant group differences existed at baseline (age, ethnicity, type of glaucoma) and no adjusted analyses are provided.

Le et al. (2019) conducted a retrospective single-center cohort study to analyze the surgical outcomes from 2011 to 2017, of patients with mild POAG after combined phacoemulsification with either iStent implantation (48 eyes) or goniotomy using KDB (29 eyes) with a minimum of 12 months follow-up. There was no difference in patients age, previous surgery, sex, preoperative or postoperative visual acuity or IOP between the 2 groups. The overall percentage of IOP reduction was 14.3% in the iStent group and 12.6% in the KDB group at 12 months of follow-up. Mean topical glaucoma medication use decreased from  $2.0 \pm 0.9$  to  $0.7 \pm 1.1$  in the iStent group and from  $2.2 \pm 1.0$  to  $1.6 \pm 1.3$  in the KDB group. Adjusted analyses failed to detect statistically significant group differences. The authors concluded phaco in combination with either iStent implantation or goniotomy using the KDB both achieved statistical significance in IOP reduction and number of



glaucoma medications at 12-month follow-up. Limitations in the study include small sample size, which could have been insufficient to detect clinically significant group differences (type 2 error), and short-term follow-up.

A multicenter retrospective observational comparative study was conducted by Dorairaj et al. (2018), comparing IOP outcomes in eyes with cataract and glaucoma undergoing phaco in combination with goniotomy using the KDB or implantation of a single iStent trabecular bypass device. Preoperative, intraoperative and postoperative data of IOP and IOP lowering medications were collected through 6 months of follow-up in 435 eyes of 318 subjects in phaco-goniotomy with KDB (n = 237) or phaco-iStent (n = 198). The results showed mean IOPs were not statistically different between groups at all time points (1 day, 1 week, and 1, 3, and 6 months) postoperatively. The percent change in IOP from baseline identified statistically significantly greater reduction in phaco-goniotomy with KDB group versus the phaco-iStent group at all time points ( $p < 0.001$ ). Additionally, the proportion of eyes achieving IOP reduction  $\geq 20\%$  was statistically greater in the phaco-goniotomy with KDB group than in the phaco-iStent group at every time point after day 1 ( $p \leq 0.011$ ). IOP-lowering medication reduction was greater in the phaco-goniotomy with KDB group compared to the phaco-iStent group ( $p = 1.1$  vs.  $0.9$  medications, respectively;  $p = 0.001$ ). The most common AE was IOP spikes occurring in 12.6% of phaco-iStent eyes and 6.3% of phaco-goniotomy with KDB eyes ( $p = 0.024$ ). However, the phaco-iStent group had a lower baseline IOP than the phaco-goniotomy with KDB group thereby slightly reducing the dynamic range between the starting IOP and the episcleral pressure compared to the dynamic range for the phaco-goniotomy with KDB group. The authors concluded goniotomy with the KDB combined with cataract surgery significantly lowers both IOP and the need for IOP-lowering medications compared to cataract extraction with iStent implantation in glaucomatous eyes through 6 months. The authors noted some surgeons are implanting two iStent devices to optimize the IOP-lowering effect. Future studies comparing the use of double iStent implants with goniotomy using the KDB should be examined. Limitations in the study included the retrospective design, short-term follow-up, lack of randomization, which could have led to confounding by indication or other forms of biases, no postoperative management protocol, efficacy measurement of IOP, and author conflict of interest with manufacturer.

Grover et al. (2018, included in the systematic review by Guo et al. 2020 discussed above) conducted a retrospective chart review case series of patients with various types of OAG who underwent a GATT. The purpose of the study was to provide 24-month follow-up on surgical success and safety. A total of 198 patients (198 eyes) between 24 to 89 years of age with IOP of  $\geq 18$  mmHg underwent GATT. Patients were stratified into 6 groups: 1) POAG with no prior CE, receiving only GATT; 2) POAG with no prior CE, receiving combined GATT and CE; 3) POAG with prior CE, receiving only GATT; 4) Other glaucoma with no prior CE, receiving only GATT; 5) Other glaucoma with no prior CE, receiving combined GATT and CE; and 6) Other glaucoma with prior CE, receiving only GATT. At 24 months, patients with primary OAG (groups 1–3, n = 72) had an average IOP decrease of 9.2 mmHg and an average decrease of 1.43 glaucoma medications. The mean percentage of IOP decrease in these POAG groups at 24 months was 37.3%. In patients with SOAG (groups 4–6, n = 49), there was an average decrease in IOP of 14.1 mmHg and an average of 2.0 fewer medications. The mean percentage of IOP decrease in the SOAG groups at 24 months was 49.8%. The cumulative proportion of failure at 24 months ranged from 0.18 to 0.48, depending on the group. In all 6 study groups, at all 5 postoperative time points (3, 6, 12, 18, and 24 months) the mean IOP and reduction in glaucoma medications was significantly reduced from baseline ( $p < 0.001$ ) with the exception of one time point (i.e., the POAG Prior CE group, at 24 months, reduction in glaucoma medication,  $p = 0.059$ ). The authors concluded that the 24-month results demonstrate that GATT is relatively safe and effective in treating various forms of OAG. They noted that long-term results for GATT are relatively equivalent to those previously reported for GATT and ab externo trabeculectomy studies. However, limitations of this study should be noted. For example, all cases are from a single glaucoma center, the decision for this particular surgical intervention was based on the individual surgeon's discretion rather than a randomization scheme, the number of patients who were lost to follow-up or censored after reoperation, and the study design, which is prone to selection bias, missing data, inaccuracies and lacks a control. Multi-center randomized controlled trials with longer follow-up are still needed to ensure the safety and efficacy of GATT.

Bussel et al. (2015) conducted a prospective interventional cohort study evaluating the outcomes of AIT and phaco-AIT with trabectome following failed trabeculectomy. The study included participants with a diagnosis of glaucoma (with or without visually significant cataract) who failed trabeculectomy at least three months prior and had at least 1 year of follow-up. A total of seventy-three eyes of 73 patients were assessed for IOP, medications, complications, secondary procedures and success. Success was defined as IOP less than 21 mmHg and greater than 20% reduction from baseline without further surgery. The results showed AIT performed alone showed a statistically significant decrease in IOP and in the number of glaucoma medications, while phaco-AIT resulted in a similar trend but did not reach statistical significance for medications. AEs included transient hypotony occurred (7%) and further glaucoma surgery (18%) was necessary within 1 year. The authors concluded AIT can be considered a viable therapeutic option for patients with a history of previously failed trabeculectomy who require further IOP lowering and are unable to tolerate conventional glaucoma surgery. Limitations of the study include potential selection bias, limited sample size, relatively short follow-up, and lack of comparison group undergoing interventions other than AIT.



## ***Clinical Practice Guidelines***

### **American Academy of Ophthalmology (AAO)**

The 2020 AAO Preferred Practice Patterns on POAG state that while several other glaucoma surgeries exist as alternatives to trabeculectomy and aqueous shunt implantation (e.g., nonpenetrating procedures, MIGS), the precise role of these procedures in the surgical management of glaucoma remains to be determined.

The guideline states that iStent, iStent *inject* and XEN Gel Stent studies were of insufficient quality (i.e., the estimate of the effect is very uncertain) and therefore, the use of these devices should be left to the discretion of the treating ophthalmologist, in consultation with the individual patient. The guideline also states that Hydrus Microstent studies were of moderate quality and that the desirable effects of this device clearly outweigh the undesirable effects. On the topic of combining glaucoma and cataract surgery, the guideline states:

- The decision of which procedure(s) to perform first or whether to combine cataract and glaucoma surgery is determined by the ophthalmologist and patient.
- Generally, combined cataract and glaucoma surgery is not as effective as glaucoma surgery alone in lowering IOP, so patients who require filtration surgery who also have mild cataract may be better served by filtration surgery alone and cataract surgery later.
- A systematic review published in 2002 found moderate quality evidence that separating the cataract and glaucoma incisions results in lower IOP than a one-site combined procedure, but the differences in outcomes were small. Subsequent publications have found no difference between the 2 approaches (Prum et al., 2016).

An AAO Technology Assessment on novel glaucoma procedures (Francis et al., 2011) provided an evidence-based summary of clinically relevant information on novel devices for treating OAG (e.g., iStent<sup>®</sup>, EX-PRESS<sup>™</sup> mini glaucoma shunt, SOLX<sup>®</sup> Gold Shunt). The authors concluded that the novel glaucoma surgeries studied all showed some promise as alternative treatments to lower IOP in the treatment of OAG. However, their report states that it is not possible to conclude whether these novel procedures are superior, equal to, or inferior to surgery such as trabeculectomy or to one another.

An AAO Ophthalmic Technology Assessment by Minckler et al. (2008) provided an evidence-based summary of commercially available aqueous shunts currently used in substantial numbers (Ahmed, Baerveldt, Krupin, and Molteno) that are used to control IOP in various glaucomas. Although the primary indication for aqueous shunts is when prior medical or surgical therapy has failed, they may be used as primary surgical therapy for selected conditions such as trauma, chemical burns, or pemphigoid (level III evidence - case series, case reports, and poor-quality cohort and case-control studies). Based on level I evidence, aqueous shunts seem to have benefits (IOP control, duration of benefit) comparable with those of trabeculectomy in the management of complex glaucomas (phakic or pseudophakic eyes after prior failed trabeculectomies). Level I evidence indicates that there are no advantages to the adjunctive use of anti-fibrotic agents or systemic corticosteroids with currently available shunts. Too few high-quality direct comparisons of various available shunts have been published to assess the relative efficacy or complication rates of specific devices beyond the implication that larger-surface-area explants provide more enduring and better IOP control. Long-term follow-up and comparative studies are encouraged.

### ***National Institute for Health and Care Excellence (NICE)***

An interventional procedure guidance published by NICE concluded that after systematic review and meta-analysis of multiple clinical studies on almost 3,100 participants, current evidence demonstrates that trabecular stent bypass microsurgery for OAG is safe and effective (2017).

## **U.S. Food and Drug Administration (FDA)**

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

### **Viscocanalostomy, Canaloplasty, and Trabeculotomy**

Specialized devices used for viscocanalostomy and canaloplasty are regulated by the FDA as Class II devices. Additional information under product codes HMX (cannula, ophthalmic), MPA (endoilluminator), or MRH (pump, infusion, ophthalmic) is available at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed February 16, 2023)

The Canaloplasty Ophthalmic Microcannula, or iTRACK (K062259), is a flexible microcannula designed to allow atraumatic cannulation of spaces in the eye such as the AC and posterior segment, for infusion and aspiration of fluids during surgery, including saline and viscoelastics. The FDA approved the Ophthalmic Microcannula in August 2006. Additional information is available at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>.

(Accessed February 16, 2023)

The OMNI Surgical System is a handheld, manually operated device used by ophthalmologists to access, microcatheterize, and viscodilate SC ("canaloplasty") and to re-access SC and cut trabecular meshwork tissue ("trabeculotomy"). Additional information under product codes MRH (pump, infusion, ophthalmic) and HMZ (trabeculotomy) is available at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed February 16, 2023)

## **Glaucoma Drainage Devices**

The EX-PRESS™ Mini Glaucoma Shunt (K030350), indicated for use in reduction of IOP in patients with glaucoma where medical and conventional surgical treatments have failed, received 501(k) approval on March 26, 2002. Additional information is available at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed February 16, 2023)

Predicate devices include the Molteno implant (K890598 and K902489), the Baerveldt glaucoma implant (K905129 and K955455), the Krupin eye valve (K885125 and K905703), and the Ahmed glaucoma valve implant (K925636). Additional information under product code KYF (implant, eye valve) is available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed February 16, 2023)

iStent® Trabecular Micro-Bypass Stent System, Model GTS100R/L, was approved by the FDA on June 25, 2012. This device is approved for use in combination with cataract surgery to reduce IOP in adult patients with mild to moderate OAG and a cataract who are currently being treated with medication to reduce IOP. The iStent *inject*® Trabecular Micro-Bypass System (Model G2-M-IS) received FDA approval through the Premarket Approval (PMA) process ([P170043](#)) on June 21, 2018. The device is approved only for use in conjunction with cataract surgery; use in a standalone procedure would be considered "off-label." Additional information is available at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed February 16, 2023)

Hydrus® Microstent (P170034) was approved by the FDA on August 10, 2018. This device is approved for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild to moderate POAG. Additional information is available at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed February 16, 2023)

The XEN glaucoma treatment system (K161457) was approved by the FDA on November 21, 2016. This device is used to reduce intraocular pressure for the management of glaucoma. Additional information is available at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed February 16, 2023)

## **References**

Ahmed IIK, De Francesco T, Rhee D, et al. HORIZON Investigators. Long-term outcomes from the HORIZON randomized trial for a Schlemm's canal microstent in combination cataract and glaucoma surgery. *Ophthalmology*. 2022 Jul;129(7):742-751.

Ahmed IIK, Fea A, Au L, et al. A prospective randomized trial comparing Hydrus and iStent micro-invasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: the COMPARE Study. *Ophthalmology* 2019;18:S0161-6420.

Ahmed IIK, Rhee DJ, Jones J, et al; HORIZON Investigators. Three-year findings of the HORIZON Trial: A Schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract. *Ophthalmology*. 2021 Jun;128(6):857-865.

Aktas Z, Ucgul AY, Ozdek S, et al. Outcomes of gonioscopy-assisted transluminal trabeculotomy in vitrectomized patients with secondary glaucoma after silicone oil removal. *J Glaucoma*. 2021 Mar 1;30(3):e114-e118.

Al-Mugheiry TS, Cate H, Clark A, et al. Microinvasive glaucoma stent (MIGS) surgery with concomitant phakoemulsification cataract extraction: outcomes and the learning curve. *J Glaucoma*. 2017 Jul;26(7):646-651.

American Academy of Ophthalmology (AAO). American Academy of Ophthalmic Executives; Fact sheet: goniotomy. January 2023.

American Academy of Ophthalmology (AAO). Preferred Practice Pattern Guidelines. Primary open-angle glaucoma. AAO PPP Glaucoma Committee. 2020. Available from: <https://www.aao.org/preferred-practice-pattern/primary-open-angle-glaucoma-ppp>.

Arriola-Villalobos P, Martínez-de-la-Casa JM, Díaz-Valle D, et al. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. *Br J Ophthalmol*. 2012 Jan 23.

Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, et al. Glaukos iStent *inject*<sup>®</sup> trabecular micro-bypass implantation associated with cataract surgery in patients with coexisting cataract and open-angle glaucoma or ocular hypertension: A long-term study. *J Ophthalmol*. 2016;2016:1056573.

Ates H, Palamar M, Yagci A, et al. Evaluation of EX-PRESS mini glaucoma shunt implantation in refractory post-penetrating keratoplasty glaucoma. *J Glaucoma*. 2010 Oct-Nov;19(8):556-60.

Baykara M, Poroy C, Erseven C. Surgical outcomes of combined gonioscopy-assisted transluminal trabeculotomy and cataract surgery. *Indian J Ophthalmol*. 2019 Apr;67(4):505-508.

Belkin A, Chaban YV, Waldner D, et al. Gonioscopy-assisted transluminal trabeculotomy is an effective surgical treatment for uveitic glaucoma. *Br J Ophthalmol*. 2021 Dec 20;bjophthalmol-2021-320270.

Belovay GW, Naqi A, Chan BJ, et al. Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucoma. *J Cataract Refract Surg*. 2012;38(11):1911-1917.

Budenz DL, Barton K, Feuer WJ, et al. Ahmed Baerveldt Comparison Study Group. Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up. *Ophthalmology*. 2011 Mar;118(3):443-52.

Buffault J, Baudouin C, Labbé A. XEN<sup>®</sup> Gel Stent for management of chronic open angle glaucoma: A review of the literature. *J Fr Ophtalmol*. 2019 Feb;42(2):e37-e46.

Bussell II, Kaplowitz K, Schuman JS, et al. Outcomes of ab interno trabeculectomy with the trabectome after failed trabeculectomy. *British Journal of Ophthalmology* 2015;99:258-262.

Chen TC, Chen PP, Francis BA, Junk AK, Smith SD, Singh K, Lin SC. Pediatric glaucoma surgery: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2014 Nov;121(11):2107-15.

Chen XZ, Liang ZQ, Yang KY, et al. The outcomes of XEN Gel Stent implantation: A systematic review and meta-analysis. *Front Med (Lausanne)*. 2022 Feb 4;9:804847.

Clement CI, Howes F, Ioannidis AS, et al. One-year outcomes following implantation of second-generation trabecular micro-bypass stents in conjunction with cataract surgery for various types of glaucoma or ocular hypertension: multicenter, multi-surgeon study. *Clin Ophthalmol*. 2019 Mar 13;13:491-499.

De Gregorio A, Pedrotti E, Russo L, et al. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. *Int Ophthalmol*. 2018 Jun;38(3):1129-1134.

de Jong LA. The EX-PRESS glaucoma shunt versus trabeculectomy in open-angle glaucoma: a prospective randomized study. *Adv Ther*. 2009 Mar;26(3):336-45.

de Jong L, Lafuma A, Aguadé AS, et al. Five-year extension of a clinical trial comparing the EX-PRESS glaucoma filtration device and trabeculectomy in primary open-angle glaucoma. *Clin Ophthalmol*. 2011;5:527-533.

Dietlein TS, Jordan JF, Schild A, et al. Combined cataract-glaucoma surgery using the intracanalicular Eyepass glaucoma implant: first clinical results of a prospective pilot study. *J Cataract Refract Surg*. 2008 Feb;34(2):247-52.

Dorairaj SK, Kahook MY, Williamson BK, et al. A multicenter retrospective comparison of goniotomy versus trabecular bypass device implantation in glaucoma patients undergoing cataract extraction. *Clin Ophthalmol*. 2018 Apr 30;12:791-797.

ECRI Institute. Hydrus Microstent (Ivantis, Inc.) for treating open-angle glaucoma during cataract surgery. Plymouth Meeting (PA): ECRI Institute; 2019 Jul 31. (Custom Product Brief).

ECRI. iStent *inject* Trabecular Microbypass System (Glaukos Corp.) for treating open-angle glaucoma during cataract surgery. Plymouth Meeting (PA): ECRI Institute; 2019 Nov 25. (Custom Product Brief).

ECRI. Kahook Dual Blade (New World Medical, Inc.) for Standalone Goniotomy. Plymouth Meeting (PA): ECRI; 2020 Apr 29. (Custom Product Brief). Updated April 2023. ECRI. Omni Surgical System (Sight Sciences, Inc.) for treating open-angle glaucoma. Plymouth Meeting (PA): ECRI; 2021 Jan 29. (Clinical Evidence Assessment).

ECRI. Trabectome (MicroSurgical Technology, Inc.) for Treating Glaucoma. Plymouth Meeting (PA): ECRI; 2021 Jan 26. (Clinical Evidence Assessment).

ECRI. XEN Gel Stent (Allergan plc) for treating open-angle glaucoma. Plymouth Meeting (PA): ECRI; 2021 Mar 2. (Clinical Evidence Assessment).

EIMallah MK, Seibold LK, Kahook MY, et al; KDB Goniotomy Study Group. 12-month retrospective comparison of Kahook dual blade excisional goniotomy with iStent trabecular bypass device implantation in glaucomatous eyes at the time of cataract surgery. *Adv Ther.* 2019 Sep;36(9):2515-2527.

Falkenberry S, Singh IP, Crane CJ, et al. Excisional goniotomy vs trabecular microbypass stent implantation: a prospective randomized clinical trial in eyes with mild to moderate open-angle glaucoma. *J Cataract Refract Surg.* 2020 Aug;46(8):1165-1171.

Fea AM, Ahmed II, Lavia C, et al. Hydrus Microstent compared to selective laser trabeculoplasty in primary open angle glaucoma: one-year results. *Clin Exp Ophthalmol.* 2017a Mar;45(2):120-127.

Fea AM, Rekas M, Au L. Evaluation of a Schlemm's canal scaffold microstent combined with phacoemulsification in routine clinical practice: Two-year multicenter study. *J Cataract Refract Surg.* 2017b Jul;43(7):886-891.

Fellenbaum PS, Almeida AR, Minckler DS, et al. Krupin disk implantation for complicated glaucomas. *Ophthalmology.* 1994 Jul;101(7):1178-82.

Francis BA, Singh K, Lin SC, et al. Novel glaucoma procedures: A report by the American Academy of Ophthalmology. *Ophthalmology.* 2011;118(7):1466-1480.

Gagrani M, Garg I, Ghate D. Surgical interventions for primary congenital glaucoma. *Cochrane Database Syst Rev.* 2020 Aug 25;8:CD008213.

Galal A, Bilgic A, Eltanamly R, Osman A. XEN glaucoma implant with mitomycin C 1-year follow-up: result and complications. *J Ophthalmol.* 2017;2017:5457246.

Gallardo MJ, Pyfer MF, Vold SD, et al. Canaloplasty and trabeculotomy combined with phacoemulsification for glaucoma: 12-month results of the GEMINI study. *Clin Ophthalmol.* 2022 Apr 21;16:1225-1234.

Gallardo MJ, Sarkisian SR Jr, Vold SD, et al. Canaloplasty and trabeculotomy combined with phacoemulsification in open-angle glaucoma: Interim results from the GEMINI study. *Clin Ophthalmol.* 2021;15:481-489. Published 2021 Feb 10.

Gallardo MJ, Supnet RA, Ahmed IIK. Circumferential viscodilation of Schlemm's canal for open-angle glaucoma: ab-interno vs. ab-externo canaloplasty with tensioning suture. *Clin Ophthalmol.* 2018b Dec 5;12:2493-2498.

Gallardo MJ, Supnet RA, Ahmed IIK. Viscodilation of Schlemm's canal for the reduction of IOP via an ab-interno approach. *Clin Ophthalmol.* 2018a Oct 23;12:2149-2155.

Gedde SJ, Schiffman JC, Feuer WJ, et al.; Tube Versus Trabeculectomy Study Group. Three-year follow-up of the tube versus trabeculectomy study. *Am J Ophthalmol.* 2009 Nov;148(5):670-84.

Gonnermann J, Bertelmann E, Pahlitzsch M, et al. Contralateral eye comparison study in MICS & MIGS: Trabectome® vs. iStent Inject®. *Graefes Arch Clin Exp Ophthalmol.* 2017 Feb;255(2):359-365.

Grabska-Liberek I, Duda P, Rogowska M, et al. 12-month interim results of a prospective study of patients with mild to moderate open-angle glaucoma undergoing combined viscodilation of Schlemm's canal and collector channels and 360° trabeculotomy as a standalone procedure or combined with cataract surgery. *Eur J Ophthalmol.* 2021 Feb 24:1120672121998234.

Gramer E, Tausch M, Kraemer C. Time of diagnosis, reoperations and long-term results of goniotomy in the treatment of primary congenital glaucoma: a clinical study. *Int Ophthalmol.* 1996-1997;20(1-3):117-23.

Grover DS, Flynn WJ, Bashford KP, et al. Performance and safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. *Am J Ophthalmol.* 2017b Aug 4. pii: S0002-9394(17)30324-0.

Grover DS, Godfrey DG, Smith O, et al. Outcomes of gonioscopy-assisted transluminal trabeculotomy (GATT) in eyes with prior incisional glaucoma surgery. *J Glaucoma.* 2017a Jan;26(1):41-45.

Grover DS, Smith O, Fellman RL, et al. Gonioscopy-assisted transluminal trabeculotomy: an ab interno circumferential trabeculotomy: 24 months follow-up. *J Glaucoma.* 2018 May;27(5):393-401.

Guedes RAP, Gravina DM, Lake JC, et al. Intermediate results of iStent or iStent inject implantation combined with cataract surgery in a real-world setting: A longitudinal retrospective study. *Ophthalmol Ther.* 2019 Mar;8(1):87-100.

Guo CY, Qi XH, Qi JM. Systematic review and meta-analysis of treating open angle glaucoma with gonioscopy-assisted transluminal trabeculotomy. *Int J Ophthalmol.* 2020 Feb 18;13(2):317-324.

Hayes, Inc. Health Technology Assessment. Canaloplasty for open-angle glaucoma.. Hayes, Inc. January 13, 2020. Updated April 2023.

Hayes, Inc. Health Technology Assessment. XEN glaucoma treatment system (Allergan) for treatment of open-angle glaucoma. Hayes, Inc. December 2019. Updated December 2021.



Healey PR, Clement CI, Kerr NM, et al. Standalone iStent trabecular micro-bypass glaucoma surgery: A systematic review and meta-analysis. *J Glaucoma*. 2021 Feb 15.

Hengerer FH, Auffarth GU, Riffel C, et al. Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in eyes with various types of glaucoma. *Ophthalmol Ther*. 2018 Dec;7(2):405-415.

Hengerer FH, Kohnen T, Mueller M, et al. Ab interno gel implant for the treatment of glaucoma patients with or without prior glaucoma surgery: 1-year results. *J Glaucoma* 2017;26:1130–6.

Hirsch L, Cotliar J, Vold S, et al. Canaloplasty and trabeculotomy ab interno with the OMNI system combined with cataract surgery in open-angle glaucoma: 12-month outcomes from the ROMEO study. *J Cataract Refract Surg*. 2021 Jul 1;47(7):907-915.

Ho CL, Wong EY, Walton DS. Goniosurgery for glaucoma complicating chronic childhood uveitis. *Arch Ophthalmol*. 2004 Jun;122(6):838-44.

Hu K, Shah A, Virgili G, et al. Ab interno trabecular bypass surgery with Trabectome for open-angle glaucoma. *Cochrane Database Syst Rev*. 2021 Feb 4;2(2):CD011693.

Huang H, Bao WJ, Yamamoto T, Kawase K, Sawada A. Postoperative outcome of three different procedures for childhood glaucoma. *Clin Ophthalmol*. 2018;13:1-7. Published 2018 Dec 17.

Hughes T, Traynor M. Clinical results of ab interno canaloplasty in patients with open-angle glaucoma. *Clin Ophthalmol*. 2020 Oct 29;14:3641-3650.

Islamaj E, Wubbels RJ, de Waard PWT. Primary Baerveldt versus trabeculectomy study after 5 years of follow-up. *Acta Ophthalmol*. 2020;98(4):400-407.

Jones J, Koch DD, Vold S, et al. Results from the United States cohort of the HORIZON trial of a Schlemm canal microstent to reduce intraocular pressure in primary open-angle glaucoma. *J Cataract and Refractive Surg* 2019;45(9):1305-15.

Klabe K, Kaymak H. Standalone trabeculotomy and viscodilation of Schlemm's Canal and collector channels in open-angle glaucoma using the OMNI surgical system: 24-month outcomes. *Clin Ophthalmol*. 2021 Jul 20;15:3121-3129.

Koerber NJ. Canaloplasty in one eye compared with viscocanalostomy in the contralateral eye in patients with bilateral open-angle glaucoma. *J Glaucoma*. 2012 Feb;21(2):129-34.

Krupin T, Ritch R, Camras CB, et al. A long Krupin-Denver valve implant attached to a 180 degrees scleral explant for glaucoma surgery. *Ophthalmology*. 1988 Sep;95(9):1174-80.

Lavia C, Dallorto L, Maule M, et al. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. *PLoS One*. 2017 Aug 29;12(8):e0183142.

Le C, Kazaryan S, Hubbell M, et al. Surgical outcomes of phacoemulsification followed by iStent implantation versus goniotomy with the Kahook dual blade in patients With mild primary open-angle glaucoma with a minimum of 12-month follow-up. *J Glaucoma*. 2019 May;28(5):411-414.

Mansouri K, Guidotti J, Rao HL, et al. Prospective evaluation of standalone XEN gel implant and combined phacoemulsification-XEN gel implant surgery: 1-year results. *J Glaucoma* 2018;27:140–7.

Mastropasqua L, Carpineto P, Ciancaglini M, et al. Long-term results of Krupin-Denver valve implants in filtering surgery for neovascular glaucoma. *Ophthalmologica* 1996;210:203-206.

Minckler DS, Francis BA, Hodapp EA, et al. Aqueous shunts in glaucoma: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2008 Jun;115(6):1089-98.

National Institute for Health and Care Excellence (NICE). Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. Apr 2009. Updated November 2017.

National Institute for Health and Care Excellence (NICE). Trabecular stent bypass microsurgery for open angle glaucoma. London (UK): Interventional procedure guidance [IPG 575]. February 2017.

Ondrejka S, Körber N. 360° ab-interno Schlemm's canal viscodilation in primary open-angle glaucoma. *Clin Ophthalmol*. 2019 Jul 15;13:1235-1246.

Otarola F, Virgili G, Shah A, et al. Ab interno trabecular bypass surgery with Schlemm's canal microstent (Hydrus) for open angle glaucoma. *Cochrane Database Syst Rev*. 2020 Mar 9;3(3):CD012740.

Pérez-Torregrosa VT, Olate-Pérez Á, Cerdà-Ibáñez M, et al. Combined phacoemulsification and XEN45 surgery from a temporal approach and 2 incisions. *Arch Soc Esp Oftalmol*. 2016 Sep;91(9):415-21.

Pfeiffer N, Garcia-Feijoo J, Martinez-de-la-Casa JM, et al. A randomized trial of a Schlemm's Canal microstent with phacoemulsification for reducing intraocular pressure in open-angle glaucoma. *Ophthalmology*. 2015 Jul;122(7):1283-93.

Popovic M, Campos-Moller X, Saheb H, et al. Efficacy and adverse event profile of the iStent and iStent Inject trabecular micro-bypass for open-angle glaucoma: a meta-analysis. *J Curr Glaucoma Pract*. 2018;12(2):67–84.

Prum BE Jr, Rosenberg LF, Gedde SJ, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern<sup>®</sup> Guidelines. *Ophthalmology*. 2016 Jan;123(1):P41-P111.

Pyfer MF, Gallardo M, Campbell A, et al. Suppression of diurnal (9AM-4PM) IOP fluctuations with minimally invasive glaucoma surgery: an analysis of data from the prospective, multicenter, single-Arm GEMINI study. *Clin Ophthalmol*. 2021 Sep 24;15:3931-3938.

Qiao Y, Tan C, Chen X, et al. Gonioscopy-assisted transluminal trabeculotomy versus goniotomy with Kahook dual blade in patients with uncontrolled juvenile open-angle glaucoma: a retrospective study. *BMC Ophthalmol*. 2021 Nov 16;21(1):395.

Rahmatnejad K, Pruzan NL, Amanullah S, et al. Surgical outcomes of gonioscopy-assisted transluminal trabeculotomy (GATT) in patients with open-angle glaucoma. *J Glaucoma*. 2017 Dec;26(12):1137-1143.

Rauchegger T, Angermann R, Willeit P, et al. Two-year outcomes of minimally invasive XEN Gel Stent implantation in primary open-angle and pseudoexfoliation glaucoma. *Acta Ophthalmol*. 2021 Jun;99(4):369-375.

Samuelson, T. Combined glaucoma procedures. *Cataract & Refractive Surgery Today*. July 2008.

Samuelson TW, Chang DF, Marquis R, et al. A Schlemm Canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: The HORIZON Study. *Ophthalmology*. 2019b Jan;126(1):29-37.

Samuelson TW, Katz LJ, Wells JM, et al., US iStent Study Group. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. *Ophthalmology*. 2011 Mar; 118(3):459-67.

Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of iStent Inject trabecular micro-bypass in primary open-angle glaucoma and cataract: Two-year results. *Ophthalmology*. 2019a Mar 14. pii: S0161-6420(18)31990-0.

Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation versus standalone trabeculectomy. *Ophthalmology*. 2017 Jun 7. pii: S0161-6420(17)30464-5.

Sharkawi E, Lindegger DJ, Artes PH, et al. Outcomes of gonioscopy-assisted transluminal trabeculotomy in pseudoexfoliative glaucoma: 24-month follow-up. *Br J Ophthalmol*. 2021 Jul;105(7):977-982.

SooHoo JR, Seibold LK, Kahook MY. Ab interno trabeculectomy in the adult patient. *Middle East Afr J Ophthalmol*. 2015 Jan-Mar;22(1):25-9.

Sun Y, Zhang B, Zhou R, Wang T, Deng J. Trabeculectomy and EX-PRESS implantation in open-angle glaucoma: an updated meta-analysis of randomized controlled trials. *J Ophthalmol*. 2019 Sep 24;2019:2071506.

Tan NE, Tracer N, Terraciano A, et al. Comparison of safety and efficacy between ab interno and ab externo approaches to XEN gel stent placement. *Clin Ophthalmol*. 2021 Jan 26;15:299-305.

Tanito M, Chihara E. Safety and effectiveness of gold glaucoma micro shunt for reducing intraocular pressure in Japanese patients with open angle glaucoma. *Jpn J Ophthalmol*. 2017 Sep;61(5):388-394.

The Krupin Eye Valve Filtering Surgery Study Group. Krupin eye valve with disk for filtration surgery. *Ophthalmology*. 1994 Apr;101(4):651-8.

Toneatto G, Zeppieri M, Papa V, et al. 360° ab-Interno Schlemm's Canal viscodilation with OMNI viscosurgical systems for open-angle glaucoma-midterm results. *J Clin Med*. 2022 Jan 4;11(1):259.

Tseng VL, Coleman AL, Chang MY, et al. Aqueous shunts for glaucoma. *Cochrane Database Syst Rev*. 2017 Jul 28;7:CD004918.

Ventura-Abreu N, García-Feijoo J, Pazos M, et al. Twelve-month results of ab interno trabeculectomy with Kahook Dual Blade: an interventional, randomized, controlled clinical study. *Graefes Arch Clin Exp Ophthalmol*. 2021 Sep;259(9):2771-2781.

Vold SD, Williamson BK, Hirsch L, et al. Canaloplasty and trabeculotomy with the OMNI system in pseudophakic patients with open angle glaucoma: The ROMEO Study. *Ophthalmol Glaucoma*. 2021 Mar-Apr;4(2):173-181.

Wittmann B, Huchzermeyer C, Rejdak R, et al. Eyepass glaucoma implant in open-angle glaucoma after failed conventional medical therapy: Clinical results of a 5-year follow-up. *J Glaucoma*. 2017 Apr;26(4):328-334.

XEN® Gel Stent manufacturer's website. <https://hcp.XENgelstent.com/>. Accessed March 1, 2022.

Yeung HH, Walton DS. Goniotomy for juvenile open-angle glaucoma. J Glaucoma. 2010 Jan;19(1):1-4.

## Policy History/Revision Information

Date	Summary of Changes
06/01/2024	<b>Related Policy</b> <ul style="list-style-type: none"><li>Removed reference link to the Medical Policy titled <i>Corneal Hysteresis and Intraocular Pressure Measurement (for New Jersey Only)</i> (retired Jun. 1, 2024)</li></ul>
10/01/2023	<b>Coverage Rationale</b> <ul style="list-style-type: none"><li>Revised list of unproven and not medically necessary indications for treating any type of glaucoma; replaced:<ul style="list-style-type: none"><li>“Canaloplasty (ab interno) and gonioscopy-assisted transluminal trabeculotomy (e.g., OMNI® Surgical System)” with “combined canaloplasty (ab interno) and gonioscopy-assisted transluminal trabeculotomy (e.g., OMNI® Surgical System)”</li><li>“Goniotomy or gonioscopy-assisted transluminal trabeculotomy (for all other <i>conditions</i> not [listed in the policy as proven or medically necessary])” with “goniotomy or gonioscopy-assisted transluminal trabeculotomy (for all other <i>indications</i> [not listed in the policy as proven or medically necessary])”</li></ul></li></ul> <b>Applicable Codes</b> <ul style="list-style-type: none"><li>Removed CPT codes 66184 and 66185</li><li>Added notation to indicate HCPCS codes C1889 and L8612 are not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the State of New Jersey Medicaid Program</li><li>Removed notation indicating CPT codes 65820, 66989, and 66991 are not on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the State of New Jersey Medicaid Program</li></ul> <b>Supporting Information</b> <ul style="list-style-type: none"><li>Updated <i>Description of Services</i>, <i>Clinical Evidence</i>, <i>FDA</i>, and <i>References</i> sections to reflect the most current information</li><li>Archived previous policy version CS050NJ.Q</li></ul>

## Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.